Original Article
Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus
N Engl J Med 1997; 337:161-167July 17, 1997
- Abstract
Background
We conducted a multicenter, randomized trial to compare preoperative chemoradiotherapy followed by surgery with surgery alone in patients with stage I and II squamous-cell cancer of the esophagus.
Methods
The preoperative combined therapy consisted of two one-week courses; each involved radiotherapy, in a dose of 18.5 Gy delivered in five fractions of 3.7 Gy each, and 80 mg of cisplatin per square meter of body-surface area, administered 0 to 2 days before the first day of radiotherapy. The surgical plan included one-stage en bloc esophagectomy and proximal gastrectomy by the abdominal and right thoracic routes, to be performed immediately after randomization in the group assigned to surgery alone and two to four weeks after the completion of preoperative chemoradiotherapy in the group assigned to combined therapy.
Results
A total of 297 patients entered the study; 11 were found to be ineligible, and 4 were lost to follow-up. Of the remaining 282, 139 were assigned to surgery alone and 143 to combined therapy. After a median follow-up of 55.2 months, no significant difference in overall survival was observed; the median survival was 18.6 months for both groups. As compared with the group treated with surgery alone, the group treated preoperatively had longer disease-free survival (P = 0.003), a longer interval free of local disease (P = 0.01), a lower rate of cancer-related deaths (P = 0.002), and a higher frequency of curative resection (P = 0.017). However, there were more postoperative deaths (P = 0.012) in the group treated preoperatively with chemoradiotherapy. Three prognostic factors were found to influence survival in a multivariate analysis: the disease stage, based on computed tomography; the location of the tumor; and whether the surgical resection was curative.
Conclusions
In patients with squamous-cell esophageal cancer, preoperative chemoradiotherapy did not improve overall survival, but it did prolong disease-free survival and survival free of local disease.
Media in This Article
Figure 1
Overall Survival among Patients with Esophageal Cancer Treated with Surgery Alone or with Preoperative Chemoradiotherapy Followed by Surgery (Combined Treatment).Figure 2
Disease-free Survival among Patients with Esophageal Cancer Treated with Surgery Alone or with Preoperative Chemoradiotherapy Followed by Surgery (Combined Treatment).Article Activity
- Article
Esophageal cancer is a highly malignant disease. Data from French tumor registries indicate that five-year overall survival ranges from 2 percent to 8 percent for all stages.1-3 The squamous-cell type predominates, but the incidence of adenocarcinoma of the esophagus is increasing rapidly.4
Surgical resection is the standard treatment for early esophageal cancer.5 During the past decade, outcomes with surgery have improved, as indicated by an increased rate of curative resection, a decreased rate of postoperative death, and better five-year survival.6,7 However, the proportion of patients who survive for five years remains low, ranging from 30 to 50 percent for those with stage I disease, 15 to 30 percent for those with stage IIA disease, and 5 to 15 percent for those with disease in stage IIB.5,8 Patterns of treatment failure point to the need for better control of local and distant recurrences.9-13
Several phase 2 studies have indicated that preoperative treatment with a combination of chemotherapy and irradiation (chemoradiotherapy), followed by surgery, produces a complete response, as determined pathologically, in 20 to 40 percent of patients; such combination treatment thus offers the prospect of improved survival.14 From 1985 to 1988, we conducted a phase 2 study of preoperative treatment with radiotherapy and cisplatin in 119 patients with squamous-cell carcinoma of the thoracic esophagus.15 In 101 of the 111 surgically treated patients, the resection was curative. There were eight postoperative deaths. Pathological specimens from 24 patients contained no visible cancer cells. The median survival was 18 months.15 These promising results led the Fondation Française de Cancérologie Digestive and the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Cooperative Group to initiate a prospective, multicenter, randomized trial comparing preoperative chemoradiotherapy followed by surgery with surgery alone. The main end point was overall survival. Secondary end points were disease-free survival and survival free of local disease or distant metastases.
Methods
Eligibility Criteria
Patients were included in the study if they had all of the following: invasive squamous-cell carcinoma of the thoracic esophagus; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; an age of less than 70 years; medical fitness for surgery; and a tumor judged to be resectable, according to the policy of each center. Other criteria included a leukocyte count above 3500 per cubic millimeter, a serum creatinine level of at least 1.4 mg per deciliter (120 μmol per liter), and a platelet count above 120,000 per cubic millimeter. Written informed consent was required. Patients were excluded if they had lost more than 15 percent of their body weight or if they had previously undergone treatment for this disease or any other cancer except basal-cell carcinoma of the skin.
The extent of the tumor was evaluated by clinical examination, esophagography, esophagoscopy, bronchoscopy, computed tomography (CT) of the lower neck, chest, and upper abdomen, and ultrasonography of the liver. Since endoscopic ultrasonography was not available for this study, we used a staging system based on the results of the CT scan.16 The T stage was defined by the maximal transverse diameter of the esophageal tumor: less than 1 cm (T1), between 1 and 3 cm (T2), and larger than 3 cm (T3). Tumors with invasion of any neighboring structure were classified as T4. The mediastinal and celiac lymph nodes were classified as N1 (invaded) if the maximal transverse diameter of these nodes was larger than 1 cm; otherwise, they were classified as N0.
We included patients with stage T1N0, T1N1, T2N0, T2N1, or T3N0 disease. We excluded patients with one or more of the following: a tumor located within the first 4 cm of the esophagus, metastases in cervical lymph nodes, evidence of invasion of the bronchus on bronchoscopy, and tumor classified T3N1, T4N0, or T4N1. These three stages were thought by the surgeons' panel to be usually not curable by surgical resection.
Treatment
Surgery
For tumors in the middle and lower parts of the mediastinum, the recommended resection procedure was a one-stage en bloc esophagectomy and proximal gastrectomy via the abdominal and right thoracic routes. For tumors in the upper mediastinum, an additional cervical route was recommended. In either case, a two-field lymph-node resection was recommended. In the combined-treatment group, surgery was planned two to four weeks after the last preoperative treatment and after the leukocyte and platelet counts returned to normal. Curative resection was defined by the surgeon as a macroscopically complete excision of the tumor.
Radiotherapy
The target of radiotherapy was the macroscopic tumor and enlarged lymph nodes, if any, surrounded by 5-cm proximal and distal margins and a 2-cm radial margin. The target was extended to the inferior cervical area in the case of tumors located above the carina. No attempt was made to treat systematically the anatomical mediastinum or the celiac area. The use of multiple-field techniques and daily treatment of all fields were mandatory. Irradiation was delivered in two one-week courses, separated by two weeks. During each course, five daily fractions of 3.7 Gy each were delivered. The specified dose was delivered at the intersection of the central axis of the beams, according to international guidelines.17 The delivered dose was 18.5 Gy per course, for a total of 37 Gy. The maximal recommended dose to the spinal cord was 25 Gy.
Chemotherapy
Cisplatin, at a dose of 80 mg per square meter of body-surface area, was given on an outpatient basis to patients assigned to preoperative treatment 0 to 2 days before each course of radiotherapy; standard techniques were used for hydration and alkalization. The second dose of cisplatin was reduced by 50 percent if there was a grade 1 increase in the serum creatinine level or grade 2 neutropenia, thrombocytopenia, or both, according to the classification system of the World Health Organization (WHO). Treatment with the drug was discontinued if more severe acute toxic effects developed.
Pathological Analysis
Analysis of the surgical specimen included a determination of the histologic type of the tumor, the degree of extension of the tumor through the esophageal wall, whether there was nodal involvement, and the status of proximal and distal margins. For patients treated preoperatively, the response was defined according to the Tumor Regression Grade, which ranges from 1 (indicating complete regression) to 5 (no change), as described by Mandard et al.18
Follow-up
Follow-up evaluation was performed every four months after surgery until death or the end of the study period. Each evaluation included a clinical examination, esophagography, chest radiography, and ultrasonography of the liver. Treatment failure was defined as indicated by any morphologic evidence of tumor; only the first failure in a patient, which could be local, distant, or both, was reported. Subsequent sites of involvement by tumor were not recorded. After recurrence, the patients could be treated by any method considered useful.
Randomization and Statistical Analysis
Patients were randomly assigned to a treatment group by a central office after their eligibility was established. Randomization was balanced by institution, without any other type of stratification. The two treatment groups were compared with respect to base-line characteristics with use of the t-test for continuous variables and the chi-square test for categorical variables. When necessary, Fisher's exact test was used. To detect an improvement in five-year survival from 15 percent in the surgery-alone group to 25 percent in the combined-treatment group, with a one-sided type I error of 0.05 and a power of 80 percent, a total of 256 deaths would have to occur.19 Assuming an average follow-up of five years, the intended number of randomized patients was 320. Recruitment was stopped earlier than anticipated because of a slightly higher than anticipated rate of postoperative mortality in the combined-treatment group. For each end point, the probability of successful treatment or of adverse events was estimated as a function of time by the Kaplan–Meier method,20 and all the comparisons were made with the log-rank test.21 Data on patients were analyzed according to intention-to-treat principles. Survival was calculated from the date of randomization to the most recent follow-up contact or to the date of recurrence or death and included all patients in the study. For the analyses of disease-free survival and time without local or distant recurrence, treatment was considered to have failed at the time of surgery in patients who did not undergo curative resection. All P values are two-sided.
Analysis of Prognostic Factors
The following variables were studied as potential prognostic factors with respect to overall survival: age, sex, WHO performance status, weight loss, location of the tumor, tumor stage as determined by CT, whether the resection was curative or palliative, and the status of histologic margins. A Cox-model analysis was performed that included the variables that were significant in the univariate analysis.22 The positive predictive value of the tumor-stage classification based on the CT scan was investigated in patients with curative resections in the surgery-alone group.
Results
Patients
From January 1989 to June 1995, 297 patients were enrolled. Eleven patients (five in the group assigned to surgery alone and six in the combined-treatment group) were found to be ineligible; the reasons for ineligibility were the presence of another primary cancer (in five patients), excessive weight loss (three), distant metastasis (one), previous treatment for esophageal cancer (one), and refusal on the part of the patient (one). An additional four patients were lost to follow-up after randomization. Thus, a total of 282 patients (139 assigned to surgery alone and 143 assigned to combined treatment) remained in the analysis. The two treatment groups were similar except for a slightly higher proportion of patients with WHO performance status 1 in the combined-treatment group (Table 1Table 1
Characteristics of the 282 Patients, According to Treatment Group.).Compliance with Treatment
Among the 139 patients assigned to surgery alone, 2 received preoperative chemoradiotherapy; 1 of these 2 patients and 1 other did not undergo resection because of progression of the disease outside the mediastinum. Among the 143 patients assigned to combined treatment, 1 had surgery before receiving preoperative chemoradiotherapy; 2 patients did not undergo the second course of irradiation (1 died of toxic effects and 1 had disease progression); 3 patients did not undergo the second course of chemotherapy because of toxic effects. Five patients in this group did not undergo surgery for the following reasons: disease progression (three), refusal by the patient (one), and preoperative death (one). The mean (±SD) total delivered dose of radiation was 37±3 Gy; the mean delivered dose of cisplatin per course was 77±11 mg per square meter. Cisplatin induced vomiting in 37 patients and WHO grade 3 neutropenia in 3. The median time from the end of the preoperative treatment to surgery was 21 days (range, 6 to 126).
Surgery
Overall, 275 patients underwent surgery. There was no difference in surgical procedures between the two groups; more than 80 percent of all patients had a transthoracic resection, but resection was curative in more patients in the combined-treatment group (112 of 138 vs. 94 of 137, P = 0.017). During the postoperative period, 36 (26.3 percent) of the patients in the surgery-alone group and 45 (32.6 percent) in the combined-treatment group had one or more severe complications (P = 0.249), mostly pneumonia, infections, and anastomotic leakage. The postoperative mortality was significantly higher in the combined-treatment group (17 of 138, as compared with 5 of 137 in the surgery-alone group; P = 0.012), mainly because of the higher number of patients with respiratory insufficiency (6 vs. 0) and mediastinal infection or sepsis (7 vs. 2). The average duration of hospitalization was 24±20 days in both groups. There was no significant difference in morbidity or mortality among the participating centers; five centers enrolled 80 percent of the patients.
Pathological Responses
After curative resection in the combined-treatment group, a complete pathological response was noted in 29 of 112 patients (26 percent), and 20 patients (18 percent) were scored as having a major pathological response (Table 2Table 2
Pathologically Determined Disease Stage after Curative Resection, According to Treatment Group.). Comparison of the two groups indicated a significantly lower stage of disease after preoperative treatment; this was true both for the tumor (T) stage (P = 0.001) and the nodal (N) stage (P = 0.03) determined pathologically. The number of patients with mediastinal lymph-node metastases was significantly lower in the combined-treatment group (26 of 105 who had exploratory lymph-node dissection vs. 66 of 115, P = 0.001), whereas the proportion with celiac lymph-node invasion did not differ significantly between the groups (44 of 115 vs. 48 of 117).Survival
After a median follow-up of 55.2 months, 203 patients had died. For both groups, the median survival was 18.6 months. The overall survival curves of the two groups did not differ significantly (relative risk of death in the combined-treatment group as compared with the surgery-alone group = 1.0; 95 percent confidence interval, 0.7 to 1.5; P = 0.78) (Figure 1Figure 1
Overall Survival among Patients with Esophageal Cancer Treated with Surgery Alone or with Preoperative Chemoradiotherapy Followed by Surgery (Combined Treatment).); the difference between the groups was still nonsignificant after adjustment for the difference in the WHO performance status and inclusion of all randomized patients in the analysis (P = 0.65 and P = 0.75, respectively). There was a significant difference in the proportion of deaths that were due to esophageal cancer in the two groups (87 of 101 patients who had surgery alone vs. 69 of 102 patients who received combined treatment, P = 0.002) (Table 3Table 3
Survival and Causes of Death, According to Treatment Group.).Disease-Free Survival
Overall, 178 patients had persistent or recurrent disease. In 76 patients, local control was never achieved, and among the 206 patients who had curative surgery, 102 had a recurrence (41 local, 26 distant, and 35 both). Disease-free survival was significantly longer in the combined-treatment group (relative risk of recurrence or death from cancer = 0.6; 95 percent confidence interval, 0.4 to 0.9; P = 0.003) (Figure 2Figure 2
Disease-free Survival among Patients with Esophageal Cancer Treated with Surgery Alone or with Preoperative Chemoradiotherapy Followed by Surgery (Combined Treatment).).Time without Local or Distant Recurrence
The time free of local disease was significantly longer in the combined-treatment group (relative risk of local recurrence = 0.6; 95 percent confidence interval, 0.4 to 0.9; P = 0.01), but there was no significant difference in the time to distant metastasis (relative risk = 0.7; 95 percent confidence interval, 0.4 to 1.4; P = 0.24).
Late Toxic Effects
At two years, the rates of pulmonary insufficiency, cardiac failure, and stenosis of the esophageal anastomosis were 7.2 percent, 1.4 percent, and 12.3 percent, respectively. No statistically significant difference was observed between the treatment groups.
Prognostic Factors
In the univariate analysis, survival was significantly shorter among patients with a loss of more than 5 percent of body weight (P = 0.01), a tumor whose upper part was located within 25 cm of the mandibular arch (P = 0.04), and stage N1 disease (based on the results of CT). Curative resection was associated with a significant increase in survival. In the multivariate analysis, only location of the tumor within 25 cm of the mandibular arch (relative risk of death = 1.4; 95 percent confidence interval, 1.0 to 1.9; P = 0.05), stage N1 disease (relative risk = 1.5; 95 percent confidence interval, 1.1 to 2.2; P = 0.01), and palliative rather than curative resection (relative risk = 2.3; 95 percent confidence interval, 1.7 to 3.3; P<0.001) remained statistically significant.
The positive predictive value of the disease-stage classification based on the CT scan was 76 percent for stage T1 tumors (19 tumors classified as T1 on the basis of the pathological analysis among 25 classified as T1 on the basis of the CT scan) and 84 percent for stage T3 tumors (16 of 19). For T2 lesions, it was only 22 percent (10 of 46); 7 tumors were classified as stage T1 and 29 as stage T3. The values for stages N0 and N1 were 49 percent (36 of 73) and 75 percent (15 of 20), respectively.
Discussion
We found a significant prolongation of disease-free survival among patients with squamous-cell esophageal carcinoma who received chemoradiotherapy before resection. This gain was due mainly to a local effect, as attested by a longer interval free of local disease in the combined-treatment group. Other indicators of efficacy were a higher rate of curative resection, clear-cut evidence of a lower disease stage after preoperative therapy, and a higher rate of major pathological responses. However, overall survival was not significantly different in the two groups, despite a reduced rate of death due to esophageal cancer in the combined-therapy group. The similar mortality rates may reflect excessive postoperative mortality among patients treated preoperatively with chemoradiotherapy.
The value of adjuvant treatment of esophageal cancer has been called into question by the results of several randomized trials. Preoperative irradiation,23-26 postoperative irradiation,27,28 and preoperative chemotherapy29-32 have not been efficacious. Preoperative combined chemoradiotherapy has been tested in four randomized studies of squamous-cell cancer of the esophagus. A Scandinavian trial33 assigned 217 patients either to surgery alone or to preoperative treatment (radiotherapy, chemotherapy, or sequential chemoradiotherapy). The postoperative mortality in these groups was not significantly different. Patients who received preoperative irradiation with or without chemotherapy had a significant gain in survival as compared with those treated with surgery with or without chemotherapy. However, the small number of patients in each group and the low rate of curative resection (44 percent) make the results of that study debatable. Le Prise et al.34 randomly assigned 104 patients with squamous-cell cancer to surgery or sequential preoperative chemoradiotherapy, followed by surgery. A curative resection was performed in 84 percent of the patients, and postoperative mortality was 8 percent in both groups. There were no significant differences in survival. Preliminary results of a study by Urba et al.35 in 100 patients, most (75 percent) with esophageal adenocarcinoma, suggest that preoperative concurrent chemoradiotherapy does not increase survival. In another trial,36 113 patients with adenocarcinoma located mainly in the distal part of the esophagus and the cardia were assigned to surgery or to preoperative concurrent chemoradiotherapy followed by surgery. The overall resection rate was 93 percent, and the postoperative death rates in the two groups were not significantly different. At three years, overall survival was significantly longer in the combined-treatment group (P = 0.01).
The increased number of postoperative deaths in the combined-treatment group in our study could be due to deleterious effects of the high dose of radiation per fraction or of chemoradiotherapy on lung tissue, to immunosuppression, or to malnutrition. In experimental studies, a deleterious effect of high fractional doses of radiation on lung tissues has been described, but no increase in the toxicity of radiation has been observed when cisplatin has been added.37-39 In the randomized trials discussed above, excessive acute toxic effects on the lungs were not reported with doses that varied from 1.8 to 2.67 Gy per fraction. The 3.7-Gy fractional dose used in our study probably had a detrimental effect. Furthermore, the pause between the two courses of treatment is now known to allow repopulation of tumor cells in other anatomical locations.40 In future studies, fractional doses in the 2-Gy range and continuous irradiation should be used. Improvements in chemotherapy are also possible; the combination of fluorouracil with cisplatin and radiotherapy has shown promise for the nonsurgical management of localized disease.41
Our analysis of prognostic factors showed that the determination that the disease is at stage N1 on the basis of the results of the CT scan is a powerful indicator of prognosis. This contrasts with the apparent lack of prognostic value of a determination of the N0 stage, suggesting that the CT scan–based detection of minimal pathological nodal invasion is difficult. The well-established value of the quality of the surgical resection — that is, of whether the resection is curative or not — as a prognostic factor was confirmed in our study.5,8
Preoperative chemoradiotherapy merits consideration as an adjuvant treatment for squamous-cell esophageal cancer. Future efforts should aim to improve the efficacy of the treatment while reducing its toxicity.
Presented in part at the 30th Annual Meeting of the American Society of Clinical Oncology, Dallas, May 14–17, 1994.
Supported by grants from the Ligue Départementale de Lutte contre le Cancer du Doubs, France.
Source Information
From University Hospital J. Minjoz, Besançon (J.-F.B., G.M., J.-J.P., M.M.); University Hospital Côte de Nacre, Caen (M.G.); University Hospital C. Hurriez, Lille (J.-P.T.); University Hospital St. Antoine, Paris (E.T.); Institut Gustave Roussy, Villejuif (D.E.); University Hospital A. Morvan, Brest (P.L.); and University Hospital, Schiltigheim (J.-C.O.) — all in France, and the European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium (T.S.).
Address reprint requests to Dr. Bosset at the Radiation Oncology Department, University Hospital J. Minjoz, 25030 Besançon, CEDEX, France.
Other authors were Philippe Ségol (University Hospital Côte de Nacre, Caen), Jean-Bernard Flamant (University Hospital E. Debré, Reims), Jean-Pierre Arnaud (University Hospital, Angers), Jean-Pierre Plachot (University Hospital, Amiens), Anne-Marie Mandard (Centre F. Baclesse, Caen), and Gaelle Chaillard (University Hospital J. Minjoz, Besançon).
Appendix
The following institutions of the Fondation Française de Cancérologie Digestive and the EORTC Gastrointestinal Tract Cancer Cooperative Group participated in this study: University Hospital J. Minjoz, Besançon; University Hospital Côte de Nacre, Caen; University Hospital C. Hurriez, Lille; University Hospital St. Antoine, Paris; Institut Gustave Roussy, Villejuif; University Hospital A. Morvan, Brest; University Hospital, Schiltigheim; University Hospital E. Debré, Reims; University Hospital, Angers; University Hospital, Amiens; Centre F. Baclesse, Caen; Centre Val d'Aurelle, Montpellier; and University Hospital, Dijon.
- References
References
1
Bedenne L ,Faivre J ,Boutron M-C , et al. Le cancer de l'oesophage dans le département de la Côte-d'Or. Bull Cancer (Paris) 1986;73:526-534
Web of Science | Medline2
Cherie-Challine L ,Pottier D ,Gignoux M . Épidémiologie descriptive du cancer de l'oesophage dans le département du Calvados: 520 cas (1978-1982). Gastroenterol Clin Biol 1988;12:126-132
Web of Science | Medline3
Calament G ,Cauvin J-M ,Robaszkiewicz M , et al. Traitement et survie du cancer épidermoïde de l'oesophage dans le département du Finistère entre 1984 et 1988 (716 cas). Gastroenterol Clin Biol 1993;17:9-16
Web of Science | Medline4
Blot WJ ,Devesa SS ,Kneller RW ,Fraumeni JF Jr . Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289
CrossRef | Web of Science | Medline5
Siewert JR ,Fink U ,Beckurts KTE ,Roder JD . Surgery of squamous cell carcinoma of the esophagus. Ann Oncol 1994;5:Suppl 3:1-7
Medline6
Earlam R ,Cunha-Melo JR . Oesophageal squamous cell carcinoma. I. A critical review of surgery. Br J Surg 1980;67:381-390
CrossRef | Web of Science | Medline7
Muller JM ,Erasmi H ,Stelzner M ,Zieren U ,Pichlmaier H . Surgical therapy of oesophageal carcinoma. Br J Surg 1990;77:845-857
CrossRef | Web of Science | Medline8
Roder JD ,Busch R ,Stein HJ ,Fink U ,Siewert JR . Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994;81:410-413
CrossRef | Web of Science | Medline9
Aisner J ,Forastiere A ,Aroney R . Patterns of recurrence for cancer of the lung and esophagus. Cancer Treat Symp 1983;2:87-10510
Tam PC ,Siu KF ,Cheung HC ,Ma L ,Wong J . Local recurrences after subtotal esophagectomy for squamous cell carcinoma. Ann Surg 1987;205:189-194
CrossRef | Web of Science | Medline11
Sugimachi K ,Inokuchi K ,Kuwano H ,Kai H ,Okamura T ,Okudaira Y . Patterns of recurrence after curative resection for carcinoma of the thoracic part of the esophagus. Surg Gynecol Obstet 1983;157:537-540
Web of Science | Medline12
van Lanschot JJB ,Tilanus HW ,Voormolen MHJ ,van Deelen RA . Recurrence pattern of oesophageal carcinoma after limited resection does not support wide local excision with extensive lymph node dissection. Br J Surg 1994;81:1320-1323
CrossRef | Web of Science | Medline13
Law SYK ,Fok M ,Wong J . Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 1996;83:107-111
CrossRef | Web of Science | Medline14
Fink U ,Stein HJ ,Bochtler J ,Roder JD ,Wilke HJ ,Siewert JR . Neoadjuvant therapy for squamous cell esophageal carcinoma. Ann Oncol 1994;5:Suppl 3:17-26
Web of Science | Medline15
Gignoux M ,Bosset JF . Adjuvant therapy for resectable oesophageal cancer: results of a pilot study. Anticancer Res 1989;9:1023-1024
Web of Science | Medline16
Wurtz A ,Quandalle P ,Chambon JP ,Saudemont A ,Chastanet P ,Robert Y . Corrélations entre diamètres mesurés par tomodensitométrie et extension intra-pariétale des carcinomes malpighiens de l'oesophage thoracique: a propos de 101 confrontations anatomo-radiologiques. J Chir (Paris) 1990;127:63-67
Web of Science | Medline17
Dose specification for reporting external beam therapy with photons and electrons. ICRU report 29. Washington, D.C.: International Commission on Radiation Unit and Measurements, 1978.
18
Mandard AM ,Dalibard F ,Mandard JC , et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer 1994;73:2680-2686
CrossRef | Web of Science | Medline19
Freedman LS . Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982;1:121-129
CrossRef | Medline20
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science21
Mantel N . Evaluation of survival and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline22
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22023
Launois B ,Delarue D ,Campion JP ,Kerbaol M . Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 1981;153:690-692
Web of Science | Medline24
Gignoux M ,Roussel A ,Paillot B , et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 1987;11:426-432
CrossRef | Web of Science | Medline25
Wang M ,Gu XZ ,Yin WB ,Huang GJ ,Wang LJ ,Zhang DW . Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 1989;16:325-327
CrossRef | Web of Science | Medline26
Arnott SJ ,Duncan W ,Kerr GR , et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 1992;24:108-113
CrossRef | Web of Science | Medline27
Teniere P ,Hay JM ,Fingerhut A ,Fagniez P-L . Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. Surg Gynecol Obstet 1991;173:123-130
Web of Science | Medline28
Fok M ,Sham JST ,Choy D ,Cheng SW ,Wong J . Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993;113:138-147
Web of Science | Medline29
Roth JA ,Pass HI ,Flanagan MM ,Graeber GM ,Rosenberg JC ,Steinberg S . Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988;96:242-248
Web of Science | Medline30
Schlag P . Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. Arch Surg 1992;127:1446-1450
Web of Science | Medline31
Fok M, Wong J. Prospective randomized study of preoperative chemotherapy in the treatment of resectable esophageal carcinoma. In: Abstract book of the Fifth World Congress of the International Society for Diseases of the Esophagus, Kyoto, Japan, 1992:149.
32
Kok T, Tilanus H, Obertop H, et al. Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: an interim report of a randomized controlled trial. In: Abstract book of the Fifth World Congress of the International Society for Diseases of the Esophagus, Kyoto, Japan, 1992:38.
33
Nygaard K ,Hagen S ,Hansen HS , et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy: the second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-1110
CrossRef | Web of Science | Medline34
Le Prise E ,Etienne PL ,Meunier B , et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779-1784
CrossRef | Web of Science | Medline35
Urba S ,Orringer M ,Turrisi A , et al. A randomized trial comparing transhiatal esophagectomy to preoperative concurrent chemoradiation followed by esophagectomy in loco regional esophageal carcinoma. Proc Am Soc Clin Oncol 1995;14:475-475 abstract.36
Walsh TN ,Noonan N ,Hollywood D ,Kelly A ,Keeling N ,Hennessy TPJ . A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467
Full Text | Web of Science | Medline37
von der Maase J ,Overgaard J ,Vaeth M . Effect of cancer chemotherapeutic drugs on radiation-induced lung damage in mice. Radiother Oncol 1986;5:245-257
CrossRef | Web of Science | Medline38
Giri PGS ,Kimler BF ,Giri UP ,Cox GG ,Reddy EK . Comparison of single, fractionated and hyperfractionated irradiation on the development of normal tissue damage in rat lung. Int J Radiat Oncol Biol Phys 1985;11:527-534
CrossRef | Web of Science | Medline39
Van Dyk J ,Mah K ,Keane TJ . Radiation-induced lung damage:dose-time-fractionation considerations. Radiother Oncol 1989;14:55-69
CrossRef | Web of Science | Medline40
Fowler JF ,Lindstrom MJ . Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:457-467
CrossRef | Web of Science | Medline41
Herskovic A ,Martz K ,Al-Sarraf M , et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598
Full Text | Web of Science | Medline
- Citing Articles (419)
Citing Articles
1
Fuat Sayir, Ufuk Cobanoglu, Abidin Sehitogullari. (2012) The use of Ligasure Vessel Sealing System in Ivor Lewis Esophagectomy. Journal of Cardiothoracic Surgery 7:1, 10
CrossRef2
Gaurav Kumar, Sheh Rawat, Abhishek Puri, Manoj Kumar Sharma, Pranav Chadha, Anand Giri Babu, Girigesh Yadav. (2011) Analysis of dose–volume parameters predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-conformal radiation therapy or IMRT. Japanese Journal of Radiology
CrossRef3
M. Hingorani, T. Crosby, A. Maraveyas, S. Dixit, A. Bateman, R. Roy. (2011) Neoadjuvant Chemoradiotherapy for Resectable Oesophageal and Gastro-oesophageal Junction Cancer—Do We Need Another Randomised Trial?. Clinical Oncology 23:10, 696-705
CrossRef4
M. van Heijl, S.S.K.S. Phoa, M.I. van Berge Henegouwen, J.M.T. Omloo, B.M. Mearadji, G.W. Sloof, P.M.M. Bossuyt, M.C.C.M. Hulshof, D.J. Richel, J.J.G.H.M. Bergman, F.J.W. ten Kate, J. Stoker, J.J.B. van Lanschot. (2011) Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer. European Journal of Surgical Oncology (EJSO) 37:12, 1064-1071
CrossRef5
George W. Dittrick, Jill M Weber, Ravi Shridhar, Sarah Hoffe, Marcovalerio Melis, Khaldoun Almhanna, James Barthel, James McLoughlin, Richard C. Karl, Kenneth L. Meredith. (2011) Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy. Annals of Surgical Oncology
CrossRef6
Jae Won Park, Jong Hoon Kim, Eun Kyung Choi, Sang-wook Lee, Sang Min Yoon, Si Yeol Song, Yu Sun Lee, Sung Bae Kim, Seung il Park, Seung Do Ahn. (2011) Prognosis of Esophageal Cancer Patients With Pathologic Complete Response After Preoperative Concurrent Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 81:3, 691-697
CrossRef7
W-L. Chang, F-C. Lin, C-J. Yen, H. Cheng, W-W. Lai, H-B. Yang, B-S. Sheu. (2011) Tumor length assessed by miniprobe endosonography can predict the survival of the advanced esophageal squamous cell carcinoma with stricture receiving concurrent chemoradiation. Diseases of the Esophagus 24:8, 590-595
CrossRef8
Chaitan K. Narsule, Marissa M. Montgomery, Hiran C. Fernando. (2011) Evidence-Based Review of the Management of Cancers of the Gastroesophageal Junction. Thoracic Surgery Clinics
CrossRef9
Christoph Pöttgen, Martin Stuschke. (2011) Radiotherapy versus surgery within multimodality protocols for esophageal cancer – A meta-analysis of the randomized trials. Cancer Treatment Reviews
CrossRef10
A. Herskovic, W. Russell, M. Liptay, M. J. Fidler, M. Al-Sarraf. (2011) Esophageal carcinoma advances in treatment results for locally advanced disease: review. Annals of Oncology
CrossRef11
Dong Hoe Koo, Seung-Il Park, Yong-Hee Kim, Jong Hoon Kim, Hwoon-Yong Jung, Gin-Hyug Lee, Kee Don Choi, Ho June Song, Ho Young Song, Ji Hoon Shin, Kyung-Ja Cho, Dok-Hyun Yoon, Sung-Bae Kim. (2011) Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemotherapy and Pharmacology
CrossRef12
Jae Y. Kim, Arlene M. Correa, Ara A. Vaporciyan, Jack A. Roth, Reza J. Mehran, Garrett L. Walsh, David C. Rice, Jaffer A. Ajani, Dipen M. Maru, Manoop S. Bhutani, James Welsh, Edith M. Marom, Stephen G. Swisher, Wayne L. Hofstetter. (2011) Does the Timing of Esophagectomy After Chemoradiation Affect Outcome?. The Annals of Thoracic Surgery
CrossRef13
Caroline Vande Walle, Wim P. Ceelen, Tom Boterberg, Dirk Vande Putte, Yves Van Nieuwenhove, Oswald Varin, Piet Pattyn. (2011) Anastomotic Complications After Ivor Lewis Esophagectomy in Patients Treated with Neoadjuvant Chemoradiation are Related to Radiation Dose to the Gastric Fundus. International Journal of Radiation Oncology*Biology*Physics
CrossRef14
Ryohei Kawabata, Hiroshi Imamura, Tomono Kishimoto, Shinji Kitamura, Yoshimi Hachino, Yukako Yasui, Misako Fujino, Chika Fujii, Hiroshi Furukawa. (2011) Second-line combination chemotherapy with docetaxel and nedaplatin for metastatic or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus cisplatin. Esophagus 8:3, 179-185
CrossRef15
Sheh Rawat, Gaurav Kumar, Abhishek Puri, Manoj Kumar Sharma, Anjali Kakria, Pankaj Kumar. (2011) Correlation of six-minute walk test, pulmonary function test and radiation pneumonitis in the management of carcinoma of oesophagus: A prospective pilot study. Journal of Radiotherapy in Practice 10:03, 191-199
CrossRef16
Ewout F. W. Courrech Staal, Berthe M. P. Aleman, Marie-Louise F. van Velthuysen, Annemieke Cats, Henk Boot, Edwin P. M. Jansen, Frits van Coevorden, Johanna W. van Sandick. (2011) Chemoradiation for Esophageal Cancer. American Journal of Clinical Oncology 34:4, 343-349
CrossRef17
Shannon E. Fogh, Anthony Yu, Gregory J. Kubicek, Walter Scott, Edith Mitchell, Ernest L. Rosato, Adam C. Berger. (2011) Do Elderly Patients Experience Increased Perioperative or Postoperative Morbidity or Mortality When Given Neoadjuvant Chemoradiation Before Esophagectomy?. International Journal of Radiation Oncology*Biology*Physics 80:5, 1372-1376
CrossRef18
M. Orditura, G. Galizia, F. Morgillo, E. Martinelli, E. Lieto, F. Vitiello, N. Di Martino, R. Pacelli, A. Renda, F. Ciardiello, F. De Vita. (2011) Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. Diseases of the Esophagusno-no
CrossRef19
Adil Sadiq, Kamal A. Mansour. (2011) Esophageal Cancer: Recent advances. Thoracic Cancer 2:3, 75-83
CrossRef20
Katrin M Sjoquist, Bryan H Burmeister, B Mark Smithers, John R Zalcberg, R John Simes, Andrew Barbour, Val Gebski. (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology 12:7, 681-692
CrossRef21
Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Masaki Mori, Yuichiro Doki. (2011) Multimodal treatment for resectable esophageal cancer. General Thoracic and Cardiovascular Surgery 59:7, 461-466
CrossRef22
M. Pera, R. Gallego, C. Montagut, M. Martin-Richard, M. Iglesias, C. Conill, A. Reig, C. Balague, L. Petriz, D. Momblan, J. Bellmunt, J. Maurel. (2011) Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Annals of Oncology
CrossRef23
James Welsh, Arya Amini, Anna Likhacheva, Jeremy Erasmus J., Daniel Gomez, Marta Davila, Reza J. Mehran, Ritsuko Komaki, Zhongxing Liao, Wayne L. Hofstetter, Jeffrey Lee H., Manoop S. Bhutani, Jaffer A. Ajani. (2011) Update: Modern Approaches to the Treatment of Localized Esophageal Cancer. Current Oncology Reports 13:3, 157-167
CrossRef24
Nasser K. Altorki, Paul Christos, Jeff L. Port, Paul C. Lee, Farooq Mirza, Cathy Spinelli, Roger Keresztes, Debra Beneck, Subroto Paul, Brendon M. Stiles, Yuwei Zhang, David S. Schrump. (2011) Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction. Journal of Thoracic Oncology 6:6, 1121-1127
CrossRef25
M. Kranzfelder, T. Schuster, H. Geinitz, H. Friess, P. Büchler. (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. British Journal of Surgery 98:6, 768-783
CrossRef26
Tetsuhiro Owaki, Masataka Matsumoto, Hiroshi Okumura, Yasuto Uchicado, Yoshiaki Kita, Tetsuro Setoyama, Ken Sasaki, Toshihide Sakurai, Itaru Omoto, Mario Shimada, Fuminori Sakamoto, Heiji Yoshinaka, Sumiya Ishigami, Shinichi Ueno, Shoji Natsugoe. (2011) Endoscopic ultrasonography is useful for monitoring the tumor response of neoadjuvant chemoradiation therapy in esophageal squamous cell carcinoma. The American Journal of Surgery
CrossRef27
Heikki Takala, Juha Saarnio, Heikki Wiik, Pasi Ohtonen, Ylermi Soini. (2011) HIF-1α and VEGF are Associated with Disease Progression in Esophageal Carcinoma. Journal of Surgical Research 167:1, 41-48
CrossRef28
Pei-Chun Chen, Yen-Ching Chen, Liang-Chuan Lai, Mong-Hsun Tsai, Shin-Kuang Chen, Pei-Wen Yang, Yung-Chie Lee, Chuhsing K. Hsiao, Jang-Ming Lee, Eric Y. Chuang. (2011) Use of Germline Polymorphisms in Predicting Concurrent Chemoradiotherapy Response in Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef29
Baldassarre Stea, Lisa J. Hazard, Victor J. Gonzalez, Russell Hamilton. (2011) The role of radiation therapy in the control of locoregional and metastatic cancer. Journal of Surgical Oncology 103:6, 627-638
CrossRef30
Urs Zingg, Bernard M. Smithers, David C. Gotley, Garett Smith, Ahmad Aly, Anthony Clough, Adrian J. Esterman, Glyn G. Jamieson, David I. Watson. (2011) Factors Associated with Postoperative Pulmonary Morbidity After Esophagectomy for Cancer. Annals of Surgical Oncology 18:5, 1460-1468
CrossRef31
Jang-Ming Lee, Pei-Wen Yang, Shi-Yi Yang, Tzu-Hsuen Chuang, En-Chi Tung, Jin-Shing Chen, Pei-Ming Huang, Yung-Chie Lee. (2011) Genetic Variants in DNA Repair Predicts the Survival of Patients with Esophageal Cancer. Annals of Surgery 253:5, 918-927
CrossRef32
Álvaro Díaz de Liaño Argüelles, Gustavo Sánchez García, Concepción Yárnoz Irazábal, Alicia Artajona Rosino. (2011) Complicaciones de la anastomosis esofagogástrica en la operación de Ivor Lewis. Cirugía Española 89:3, 175-181
CrossRef33
Autumn J McRee, Stacy Cowherd, Andrew Z Wang, Richard M Goldberg. (2011) Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncology 7:3, 409-426
CrossRef34
Branislav Bystricky, Alicia F.C. Okines, David Cunningham. (2011) Optimal Therapeutic Strategies for Resectable Oesophageal or Oesophagogastric Junction Cancer. Drugs 71:5, 541-555
CrossRef35
Hiroshi Miyata, Makoto Yamasaki, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Koji Konishi, Eiichi Morii, Masaki Mori, Yuichiro Doki. (2011) Prognostic Value of Endoscopic Biopsy Findings After Induction Chemoradiotherapy With and Without Surgery for Esophageal Cancer. Annals of Surgery 253:2, 279-284
CrossRef36
F De Vita, M Orditura, E Martinelli, L Vecchione, R Innocenti, V C Sileni, C Pinto, M Di Maio, A Farella, T Troiani, F Morgillo, V Napolitano, E Ancona, N Di Martino, A Ruol, G Galizia, A Del Genio, F Ciardiello. (2011) A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. British Journal of Cancer 104:3, 427-432
CrossRef37
Shaun McKenzie, Brian Mailey, Avo Artinyan, Michelle Metchikian, Stephen Shibata, Kemp Kernstine, Joseph Kim. (2011) Improved Outcomes in the Management of Esophageal Cancer with the Addition of Surgical Resection to Chemoradiation Therapy. Annals of Surgical Oncology 18:2, 551-558
CrossRef38
Goran Marjanovic, Markus Schricker, Axel Walch, Axel zur Hausen, Ulrich T. Hopt, Andreas Imdahl, Frank Makowiec. (2011) Detection of Lymph Node Involvement by Cytokeratin Immunohistochemistry is an Independent Prognostic Factor After Curative Resection of Esophageal Cancer. Journal of Gastrointestinal Surgery 15:1, 29-37
CrossRef39
James Welsh, Stephen H. Settle, Arya Amini, Lianchun Xiao, Akihiro Suzuki, Yuki Hayashi, Wayne Hofstetter, Ritsuko Komaki, Zhongxing Liao, Jaffer A. Ajani. (2011) Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancern/a-n/a
CrossRef40
Álvaro Díaz de Liaño Argüelles, Gustavo Sánchez García, Concepción Yárnoz Irazábal, Alicia Artajona Rosino. (2011) Oesophagogastric anastomosis complications in the Ivor Lewis operation. Cirugía Española (English Edition) 89:3, 175-181
CrossRef41
Mark van Heijl, Jikke M. Omloo, Mark I. van Berge Henegouwen, Otto S. Hoekstra, Ronald Boellaard, Patrick M. Bossuyt, Olivier R. Busch, Hugo W. Tilanus, Maarten C. Hulshof, Ate van der Gaast, Grard A. Nieuwenhuijzen, Han J. Bonenkamp, John Th. Plukker, Miguel A. Cuesta, Fiebo J. ten Kate, Jan Pruim, Herman van Dekken, Jacques J. Bergman, Gerrit W. Sloof, J. Jan van Lanschot. (2011) Fluorodeoxyglucose Positron Emission Tomography for Evaluating Early Response During Neoadjuvant Chemoradiotherapy in Patients With Potentially Curable Esophageal Cancer. Annals of Surgery 253:1, 56-63
CrossRef42
Jennifer Y. Pan, Jaffer A. Ajani, Jian Gu, Yubo Gong, Angel Quin, Maosheng Hung, Xifeng Wu, Julie G. Izzo. (2011) Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancern/a-n/a
CrossRef43
Gang Li, Wei Hu, Jianhua Wang, Xia Deng, Ping Zhang, Xuebang Zhang, Congyin Xie, Shixiu Wu. (2010) Phase II Study of Concurrent Chemoradiation in Combination With Erlotinib for Locally Advanced Esophageal Carcinoma. International Journal of Radiation Oncology*Biology*Physics 78:5, 1407-1412
CrossRef44
Hong-Tao Liu, Ning Wang, Xin Wang, Sheng-Lei Li. (2010) Overexpression of Pim-1 is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Journal of Surgical Oncology 102:6, 683-688
CrossRef45
Matthew J. Schuchert, James D. Luketich, Rodney J. Landreneau. (2010) Management of Esophageal Cancer. Current Problems in Surgery 47:11, 845-946
CrossRef46
Sarahgene Gillianne DeFoe, Arjun Pennathur, John C. Flickinger, Dwight E. Heron, Michael K. Gibson, James D. Luketich, Joel S. Greenberger. (2010) Retrospective Review of Patients With Locally Advanced Esophageal Cancer Treated at the University of Pittsburgh. American Journal of Clinical Oncology1
CrossRef47
Srikrishna V. Patnana, Santosh B. Murthy, Lianchun Xiao, Eric Rohren, Wayne L. Hofstetter, Stephen G. Swisher, Zhongxing Liao, Jeffrey H. Lee, Manoop S. Bhutani, Homer A. Macapinlac, Xuemei Wang, Jaffer A. Ajani. (2010) Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 116:19, 4487-4494
CrossRef48
A. F. C. Okines, D. Cunningham. (2010) Multimodality treatment for localized gastro-oesophageal cancer. Annals of Oncology 21:Supplement 7, vii286-vii293
CrossRef49
Meysan Hurmuzlu, Kjell Øvrebø, Tore Wentzel-Larsen, Ludvig Paul Muren, Asgaut Viste, Rune Smaaland. (2010) High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: Correlation with dose–volume histogram parameters. Radiotherapy and Oncology 97:1, 60-64
CrossRef50
E. F. W. Courrech Staal, B. M. P. Aleman, H. Boot, M.-L. F. van Velthuysen, H. van Tinteren, J. W. van Sandick. (2010) Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. British Journal of Surgery 97:10, 1482-1496
CrossRef51
Jennifer J. Knox, Rebecca Wong, Antonio L. Visbal, Anne M. Horgan, Maha Guindi, Jennifer Hornby, Wei Xu, Jolie Ringash, Shaf Keshavjee, Eric Chen, Masoom Haider, Gail Darling. (2010) Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer 116:17, 4023-4032
CrossRef52
A. Baraniskin, A. Tannapfel, A. Reinacher-Schick. (2010) Neoadjuvante Therapie von Tumoren des oberen Gastrointestinaltrakts. Der Gastroenterologe 5:5, 412-422
CrossRef53
Nicholas W. Choong, Ann M. Mauer, Daniel C. Haraf, Mark K. Ferguson, Alan B. Sandler, Kenneth A. Kesler, Paul A. S. Fishkin, Rafat H. Ansari, James Wade, Stuart A. Krauss, David F. Sciortino, Mitchell C. Posner, Masha Kocherginsky, Philip C. Hoffman, Livia Szeto, Everett E. Vokes. (2010) Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Medical Oncology
CrossRef54
Daniel King Hung Tong, Simon Law, Dora Lai Wan Kwong, Kwok Wah Chan, Alfred King Yin Lam, Kam Ho Wong. (2010) Histological Regression of Squamous Esophageal Carcinoma Assessed by Percentage of Residual Viable Cells after Neoadjuvant Chemoradiation is an Important Prognostic Factor. Annals of Surgical Oncology 17:8, 2184-2192
CrossRef55
D.G. Power, J.V. Reynolds. (2010) Localized adenocarcinoma of the esophagogastric junction – Is there a standard of care?. Cancer Treatment Reviews 36:5, 400-409
CrossRef56
Bree N. Ruppert, John M. Watkins, Keisuke Shirai, Amy E. Wahlquist, Elizabeth Garrett-Mayer, Eric G. Aguero, Carol A. Sherman, Carolyn E. Reed, Anand K. Sharma. (2010) Cisplatin/Irinotecan Versus Carboplatin/Paclitaxel as Definitive Chemoradiotherapy for Locoregionally Advanced Esophageal Cancer. American Journal of Clinical Oncology 33:4, 346-352
CrossRef57
Abhishek Puri, Sheh Rawat, Pranav Chadha. (2010) Nonstandard Protocol for Treatment of Carcinoma Esophagus Does Not Suffice for Identification of Prognostic Markers in Retrospective Study. International Journal of Radiation Oncology*Biology*Physics 77:4, 1288
CrossRef58
Hiroshi Saeki, Takanobu Masuda, Satoko Okada, Koji Ando, Masahiko Sugiyama, Keiji Yoshinaga, Kazuya Endo, Noriaki Sadanaga, Yasunori Emi, Yoshihiro Kakeji, Masaru Morita, Natsumi Yamashita, Yoshihiko Maehara. (2010) Impact of perioperative peripheral blood values on postoperative complications after esophageal surgery. Surgery Today 40:7, 626-631
CrossRef59
Thomas Ng, Michael P. Vezeridis. (2010) Advances in the surgical treatment of esophageal cancer. Journal of Surgical Oncology 101:8, 725-729
CrossRef60
Andras Papp, Laszlo Cseke, Robert Farkas, Gabor Pavlovics, Gabor Horvath, Gabor Varga, Andras Szigeti, Szabolcs Bellyei, Sandor Marton, Laszlo Poto, Katalin Kalmar, Andras Vereczkei, Eva Pozsgai, Ors Peter Horvath. (2010) Chemo-radiotherapy in Locally Advanced Squamous Cell Oesophageal Cancer—are Upper Third Tumours more Responsive?. Pathology & Oncology Research 16:2, 193-200
CrossRef61
Takahiro Yoshida, Junichi Seike, Takanori Miyoshi, Hiromichi Yamai, Hirokazu Takechi, Yasuhiro Yuasa, Yoshihito Furukita, Yota Yamamoto, Atsushi Umemoto, Akira Tangoku. (2010) Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus. Esophagus 7:2, 95-100
CrossRef62
R. H. Mak, H. J. Mamon, D. P. Ryan, D. T. Miyamoto, M. Ancukiewicz, W. K. Kobayashi, C. G. Willett, N. C. Choi, L. S. Blaszkowsky, T. S. Hong. (2010) Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. Diseases of the Esophagus 23:4, 316-323
CrossRef63
G. Verlato, A. Zanoni, A. Tomezzoli, A. Minicozzi, S. Giacopuzzi, M. Di Cosmo, I. Franceschetti, G. de Manzoni. (2010) Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual foci. British Journal of Surgery 97:5, 719-725
CrossRef64
R. Malthaner, R.K.S. Wong, K. Spithoff. (2010) Preoperative or Postoperative Therapy for Resectable Oesophageal Cancer: an Updated Practice Guideline. Clinical Oncology 22:4, 250-256
CrossRef65
C. Pöttgen, M. Stuschke. (2010) Multimodale Therapie beim Plattenepithelkarzinom des Ösophagus. Der Onkologe 16:5, 496-503
CrossRef66
Doreen Dähn, Joachim Martell, Hilke Vorwerk, Clemens F. Hess, Heinz Becker, Klaus Jung, Reinhard Hilgers, Hendrik Andreas Wolff, Robert Michael Hermann, Hans Christiansen. (2010) Influence of Irradiated Lung Volumes on Perioperative Morbidity and Mortality in Patients After Neoadjuvant Radiochemotherapy for Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics 77:1, 44-52
CrossRef67
T. H. La, A. Y. Minn, Z. Su, G. A. Fisher, J. M. Ford, P. Kunz, K. A. Goodman, A. C. Koong, D. T. Chang. (2010) Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. Diseases of the Esophagus 23:4, 300-308
CrossRef68
Jaffer A. Ajani, Arlene M. Correa, Garrett L. Walsh, Ritsuko Komaki, Jeffrey H. Lee, Ara A. Vaporciyan, David C. Rice, James C. Yao, Dipen M. Maru, Wayne L. Hofstetter, Alexandria T. Phan, Stephen G. Swisher. (2010) Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer 116:7, 1656-1663
CrossRef69
S. Ngamruengphong, V. K. Sharma, B. Nguyen, A. Das. (2010) Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography. Diseases of the Esophagus 23:3, 216-231
CrossRef70
Alicia Okines, Bhupinder Sharma, David Cunningham. (2010) Perioperative management of esophageal cancer. Nature Reviews Clinical Oncology 7:4, 231-238
CrossRef71
Kenneth L. Meredith, Jill M. Weber, Kiran K. Turaga, Erin M. Siegel, Jim McLoughlin, Sarah Hoffe, Melis Marcovalerio, Nilay Shah, Scott Kelley, Richard Karl. (2010) Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer. Annals of Surgical Oncology 17:4, 1159-1167
CrossRef72
John R. Hyngstrom, Mitchell C. Posner. (2010) Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. Journal of Surgical Oncology 101:4, 299-304
CrossRef73
Arlene A. Forastiere. (2010) Multimodality treatment of esophagus cancer: current status and future perspectives in the United States. Esophagus 7:1, 1-6
CrossRef74
Michael Kranzfelder, Peter Büchler, Konstanze Lange, Helmut Friess. (2010) Treatment Options for Squamous Cell Cancer of the Esophagus: A Systematic Review of the Literature. Journal of the American College of Surgeons 210:3, 351-359
CrossRef75
Maryam B. Lustberg, Tanios Bekaii-Saab, Donn Young, Gregory Otterson, William Burak, Abbas Abbas, Barbara McCracken-Bussa, Mark E. Lustberg, Miguel A. Villalona-Calero. (2010) Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. Journal of Thoracic Oncology1
CrossRef76
David Schreiber, Justin Rineer, Dan Vongtama, Angela Wortham, Peter Han, David Schwartz, Kwang Choi, Marvin Rotman. (2010) Impact of Postoperative Radiation after Esophagectomy for Esophageal Cancer. Journal of Thoracic Oncology 5:2, 244-250
CrossRef77
Makoto Yamasaki, Hiroshi Miyata, Yoshiyuki Fujiwara, Shuji Takiguchi, Kiyokazu Nakajima, Toshirou Nishida, Takushi Yasuda, Jin Matsuyama, Masaki Mori, Yuichiro Doki. (2010) p53 Genotype Predicts Response to Chemotherapy in Patients with Squamous Cell Carcinoma of the Esophagus. Annals of Surgical Oncology 17:2, 634-642
CrossRef78
James M McKevith, Stephen H Pennefather. (2010) Respiratory complications after oesophageal surgery. Current Opinion in Anaesthesiology 23:1, 34-40
CrossRef79
M Byrne, J V Reynolds, J S O'Donnell, M Keogan, B White, M Byrne, S Murphy, S G Maher, G P Pidgeon. (2010) Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. British Journal of Cancer 102:1, 73-79
CrossRef80
C.M. Shahbaz Sarwar, James D. Luketich, Rodney J. Landreneau, Ghulam Abbas. (2010) Esophageal cancer: An update. International Journal of Surgery 8:6, 417-422
CrossRef81
Elfriede Bollschweiler, Arnulf H Hölscher, Ralf Metzger. (2010) Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncology 6:1, 25-35
CrossRef82
Bas P. L. Wijnhoven, Jan J. B. Lanschot, Hugo W. Tilanus, Ewout W. Steyerberg, Ate Gaast. (2009) Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Review of Meta-Analyses. World Journal of Surgery 33:12, 2606-2614
CrossRef83
M Kranzfelder, P Büchler, H Friess. (2009) Surgery within multimodal therapy concepts for esophageal squamous cell carcinoma (ESCC): the MRI approach and review of the literature. Advances in Medical Sciences 54:2, 158-169
CrossRef84
Robert Diaz, Gaspar Reynes, Alejandro Tormo, Manuel Juan, Regina Gironés, Ángel Segura, Jorge Aparicio, Paula Richart, Helena Cueva, José García. (2009) Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience. Clinical and Translational Oncology 11:12, 835-841
CrossRef85
Heta Javeri, Lianchun Xiao, Eric Rohren, Jeffrey H. Lee, Zhongxing Liao, Wayne Hofstetter, Dipen Maru, Manoop S. Bhutani, Stephen G. Swisher, Homer Macapinlac, Xuemei Wang, Jaffer A. Ajani. (2009) The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 115:22, 5184-5192
CrossRef86
R. Semrau, D. Vallböhmer, A.H. Hölscher, R.-P. Müller. (2009) Neoadjuvante Therapie der Adenokarzinome des oberen Gastrointestinaltraktes. Der Chirurg 80:11, 1035-1041
CrossRef87
Julian A. Abrams, Donna L. Buono, Joshua Strauss, Russell B. McBride, Dawn L. Hershman, Alfred I. Neugut. (2009) Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer 115:21, 4924-4933
CrossRef88
Hideomi Yamashita, Kae Okuma, Yasuyuki Seto, Kazuhiko Mori, Shino Kobayashi, Reiko Wakui, Kuni Ohtomo, Keiichi Nakagawa. (2009) A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II-III esophageal carcinoma. Journal of Surgical Oncology 100:6, 435-441
CrossRef89
B.L.D.M. Brücher. (2009) Plattenepithelkarzinom des Ösophagus. Der Chirurg 80:11, 1011-1018
CrossRef90
Hiroshi Miyata, Makoto Yamasaki, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Toshiro Nishida, Masaki Mori, Yuichiro Doki. (2009) Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. Journal of Surgical Oncology 100:6, 442-446
CrossRef91
En Loon C. Yong, Xing Peng Han, David I. Watson, Peter G. Devitt, Glyn G. Jamieson, Sarah K. Thompson. (2009) Outcome following surgery for squamous cell carcinoma of the oesophagus. ANZ Journal of Surgery 79:10, 724-728
CrossRef92
Christophe Mariette. (2009) Current standards and options in the treatment of squamous cell oesophageal carcinoma. European Journal of Cancer 45, 452-454
CrossRef93
C.G. Willett, B.G. Czito. (2009) Chemoradiotherapy in Gastrointestinal Malignancies. Clinical Oncology 21:7, 543-556
CrossRef94
T. Ruhstaller, L. Widmer, J. C. Schuller, A. Roth, V. Hess, W. Mingrone, R. von Moos, M. Borner, B. C. Pestalozzi, S. BalmerMajno, D. Koberle, L. Terraciano, A. Schnider, S. Bodis, R. Popescu, . (2009) Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of Oncology 20:9, 1522-1528
CrossRef95
Min Kyoung Kim, Kyung-Ja Cho, Seung-Il Park, Yong Hee Kim, Jong Hoon Kim, Ho-Young Song, Ji Hoon Shin, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Ho June Song, Jin-Sook Ryu, Sung-Bae Kim. (2009) Initial Stage Affects Survival Even After Complete Pathologic Remission is Achieved in Locally Advanced Esophageal Cancer: Analysis of 70 Patients With Pathologic Major Response After Preoperative Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 75:1, 115-121
CrossRef96
Bernhard Berger, Claus Belka. (2009) Evidence-based radiation oncology: Oesophagus. Radiotherapy and Oncology 92:2, 276-290
CrossRef97
Daniel T. Chang, Christopher Chapman, John Shen, Zheng Su, Albert C. Koong. (2009) Treatment of Esophageal Cancer Based on Histology. American Journal of Clinical Oncology 32:4, 405-410
CrossRef98
Karin Ribi, Dieter Koeberle, Jan C. Schuller, Hanspeter Honegger, Arnaud Roth, Viviane Hess, Peter Moosmann, Roger Moos, Markus Borner, Norbert Lombriser, Bernhard Pestalozzi, Thomas Ruhstaller. (2009) Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. Supportive Care in Cancer 17:8, 1109-1116
CrossRef99
E. van Meerten, A. van der Gaast, H.W. Tilanus, J.W. Poley, K. Muller, H. van Dekken. (2009) Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: The rotterdam experience. Journal of Surgical Oncology 100:1, 32-37
CrossRef100
Geoffrey Y. Ku, David H. Ilson. (2009) Role of Neoadjuvant Therapy for Esophageal Adenocarcinoma. Surgical Oncology Clinics of North America 18:3, 533-546
CrossRef101
Zhen Zhang, Yuan Chen, Yanzhi Chen, Melenda Jeter, Wayne L. Hofstetter, Jaffer Ajani, Stephen G. Swisher, Joe Y. Chang, Pamela K. Allen, James D. Cox, Ritsuko Komaki, Zhongxing X. Liao. (2009) Outcomes with Esophageal Cancer Radiation Therapy. Journal of Thoracic Oncology 4:7, 880-888
CrossRef102
Grace L. Smith, Benjamin D. Smith, Thomas A. Buchholz, Zhongxing Liao, Melenda Jeter, Stephen G. Swisher, Wayne L. Hofstetter, Jaffer A. Ajani, Mary F. McAleer, Ritsuko Komaki, James D. Cox. (2009) Patterns of Care and Locoregional Treatment Outcomes in Older Esophageal Cancer Patients: The SEER-Medicare Cohort. International Journal of Radiation Oncology*Biology*Physics 74:2, 482-489
CrossRef103
Marcovalerio Melis, James M. McLoughlin, E. Michelle Dean, Erin M. Siegel, Jill M. Weber, Nilay Shah, Scott T. Kelley, Richard C. Karl. (2009) Correlations Between Neoadjuvant Treatment, Anemia, and Perioperative Complications in Patients Undergoing Esophagectomy for Cancer. Journal of Surgical Research 153:1, 114-120
CrossRef104
Jan Brabender, Dariusch Arbab, Xi Huan, Daniel Vallböhmer, Peter Grimminger, Frederike Ling, Susanne Neiss, Elfriede Bollschweiler, Paul M. Schneider, Arnulf H. Hölscher, Ralf Metzger. (2009) Death-Associated Protein Kinase (DAPK) Promoter Methylation and Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer. Annals of Surgical Oncology 16:5, 1378-1383
CrossRef105
E. A. Rieff, T. Hendriks, H. J. T. Rutten, G. A. P. Nieuwenhuijzen, M. J. E. M. Gosens, A. J. C. Brule, S. W. Nienhuijs, I. H. J. T. Hingh. (2009) Neoadjuvant Radiochemotherapy Increases Matrix Metalloproteinase Activity in Healthy Tissue in Esophageal Cancer Patients. Annals of Surgical Oncology 16:5, 1384-1389
CrossRef106
Inderpal S. Sarkaria, Nabil P. Rizk, Manjit S. Bains, Laura H. Tang, David H. Ilson, Bruce I. Minsky, Valerie W. Rusch. (2009) Post-treatment Endoscopic Biopsy Is a Poor-Predictor of Pathologic Response in Patients Undergoing Chemoradiation Therapy for Esophageal Cancer. Annals of Surgery 249:5, 764-767
CrossRef107
Stephan Kersting, Ralf Konopke, Dag Dittert, Marius Distler, Felix Rückert, Jörg Gastmeier, Gustavo B Baretton, Hans D Saeger. (2009) Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?. Journal of Gastroenterology and Hepatology 24:5, 886-895
CrossRef108
Toshiyuki Sakaeda, Motohiro Yamamori, Akiko Kuwahara, Kohshi Nishiguchi. (2009) Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Advanced Drug Delivery Reviews 61:5, 388-401
CrossRef109
Norikatsu Miyoshi, Masahiko Yano, Ko Takachi, Kentaro Kishi, Shingo Noura, Hidetoshi Eguchi, Terumasa Yamada, Isao Miyashiro, Masayuki Ohue, Hiroaki Ohigashi, Yo Sasaki, Osamu Ishikawa, Yuichiro Doki, Shingi Imaoka. (2009) Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. Journal of Surgical Oncology 99:5, 302-306
CrossRef110
Björn L. D. M. Brücher, Stephen G. Swisher, Alfred Königsrainer, Derek Zieker, Jörg Hartmann, Hubert Stein, Yuko Kitagawa, Simon Law, Jaffer A. Ajani. (2009) Response to Preoperative Therapy in Upper Gastrointestinal Cancers. Annals of Surgical Oncology 16:4, 878-886
CrossRef111
J. G. Izzo, X. Wu, T.-T. Wu, P. Huang, J.-S. Lee, Z. Liao, J. H. Lee, M. S. Bhutani, W. Hofstetter, D. Maru, M.-C. Hung, J. A. Ajani. (2009) Therapy-induced expression of NF-κB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Diseases of the Esophagus 22:2, 127-132
CrossRef112
Aoife M. Ryan, John V. Reynolds, Laura Healy, Miriam Byrne, Jennifer Moore, Niamh Brannelly, Aisling McHugh, Deirdre McCormack, Philomena Flood. (2009) Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) Preserves Lean Body Mass Following Esophageal Cancer Surgery: Results of a Double-Blinded Randomized Controlled Trial. Annals of Surgery 249:3, 355-363
CrossRef113
Geoffrey Y. Ku, David H. Ilson. (2009) Preoperative Therapy for Esophageal Cancer. Gastroenterology Clinics of North America 38:1, 135-152
CrossRef114
Yixing Jiang, Eric Kimchi, Jaffer A Ajani. (2009) Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach?. Future Oncology 5:2, 157-161
CrossRef115
Jaffer A. Ajani. (2009) Future Developments in Esophageal Cancer Research. Gastroenterology Clinics of North America 38:1, 183-188
CrossRef116
Amanda L. Schwer, Ari Ballonoff, Robert McCammon, Kyle Rusthoven, Ralph B. D'Agostino, Tracey E. Schefter. (2009) Survival Effect of Neoadjuvant Radiotherapy Before Esophagectomy for Patients With Esophageal Cancer: A Surveillance, Epidemiology, and End-Results Study. International Journal of Radiation Oncology*Biology*Physics 73:2, 449-455
CrossRef117
Kuang-Tai Kuo, Hao-Wei Wang, Teh-Ying Chou, Wen-Hu Hsu, Han-Shui Hsu, Chi-Hung Lin, Liang-Shun Wang. (2009) Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology 16:2, 352-360
CrossRef118
Yuji Tachimori. (2009) Role of salvage esophagectomy after definitive chemoradiotherapy. General Thoracic and Cardiovascular Surgery 57:2, 71-78
CrossRef119
Roderick M. Quiros, Courtney L. Bui. (2009) Multidisciplinary Approach to Esophageal and Gastric Cancer. Surgical Clinics of North America 89:1, 79-96
CrossRef120
Ali Salavati, Sandip Basu, Pedram Heidari, Abass Alavi. (2009) Impact of fluorodeoxyglucose PET on the management of esophageal cancer. Nuclear Medicine Communications 30:2, 95-116
CrossRef121
Heta Javeri, Lianchun Xiao, Eric Rohren, Ritsuko Komaki, Wayne Hofstetter, Jeffrey H. Lee, Dipen Maru, Manoop S. Bhutani, Stephen G. Swisher, Xuemei Wang, Jaffer A. Ajani. (2009) Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 115:3, 624-630
CrossRef122
Mark J. Krasna. (2009) Stage-Specific Therapy for Cancer of the Oesophagus. Drugs & Aging 26:3, 185-194
CrossRef123
Stephanie Servagi-Vernat, Mathieu Bosset, Gilles Crehange, Jöelle Buffet-Miny, Marc Puyraveau, Philippe Maingon, Mariette Mercier, Jean François Bosset. (2009) Feasibility of Chemoradiotherapy for Oesophageal Cancer in Elderly Patients Aged ≥75 Years. Drugs & Aging 26:3, 255-262
CrossRef124
Hisahiro Matsubara. (2008) Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. International Journal of Clinical Oncology 13:6, 474-478
CrossRef125
Thomas J Murphy, Narayamasamy Ravi, John V Reynolds. (2008) Treatment options for esophageal cancer. Expert Opinion on Pharmacotherapy 9:18, 3197-3210
CrossRef126
Christian G. Peyre, Jeffrey A. Hagen, Steven R. DeMeester, Jan J. B. Van Lanschot, Arnulf Hölscher, Simon Law, Alberto Ruol, Ermanno Ancona, S Michael Griffin, Nasser K. Altorki, Thomas W. Rice, John Wong, Toni Lerut, Tom R. DeMeester. (2008) Predicting Systemic Disease in Patients With Esophageal Cancer After Esophagectomy. Annals of Surgery 248:6, 979-985
CrossRef127
Romuald Le Scodan, Françoise Mornex, Christian Partensky, Catherine Mercier, Pierre-Jean Valette, Marc Ychou, Pascal Roy, Jean-Yves Scoazec. (2008) Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 31:6, 545-552
CrossRef128
Geoffrey Y Ku, David H Ilson. (2008) Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert Review of Anticancer Therapy 8:12, 1953-1964
CrossRef129
D Tougeron, F Di Fiore, S Thureau, N Berbera, I Iwanicki-Caron, H Hamidou, B Paillot, P Michel. (2008) Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. British Journal of Cancer 99:10, 1586-1592
CrossRef130
Takashi Kobayashi, Masanori Teruya, Tomokazu Kishiki, Daisuke Endo, Yoshiharu Takenaka, Hozumi Tanaka, Kenji Miki, Kaoru Kobayashi, Koji Morita. (2008) Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery 144:5, 729-735
CrossRef131
S Lorenzen, B Brücher, F Zimmermann, H Geinitz, J Riera, T Schuster, N Roethling, H Höfler, K Ott, C Peschel, J R Siewert, M Molls, F Lordick. (2008) Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. British Journal of Cancer 99:7, 1020-1026
CrossRef132
A. Takashima, K. Shirao, Y. Hirashima, D. Takahari, N. Okita, S. Akatsuka, T. Eguchi Nakajima, J. Matsubara, H. Yasui, T. Asakawa, K. Kato, T. Hamguchi, K. Muro, Y. Yamada, Y. Shimada. (2008) Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Diseases of the Esophagus 21:7, 607-611
CrossRef133
S. K. Seung, J. W. Smith, H. J. Ross. (2008) Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer. Diseases of the Esophagus 21:7, 589-595
CrossRef134
K. Tanaka, Y. Mohri, M. Ohi, T. Yokoe, Y. Koike, Y. Morimoto, C. Miki, H. Tonouchi, M. Kusunoki. (2008) Mitotic Checkpoint Genes, hsMAD2 and BubR1, in Oesophageal Squamous Cancer Cells and their Association with 5-fluorouracil and Cisplatin-based Radiochemotherapy. Clinical Oncology 20:8, 639-646
CrossRef135
Heta Javeri, Rohan Arora, Arlene M. Correa, Wayne L. Hofstetter, Jeffrey H. Lee, Zhongxing Liao, Mary F. McAleer, Dipen Maru, Manoop S. Bhutani, Stephen G. Swisher, Julie G. Izzo, Jaffer A. Ajani. (2008) Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 113:6, 1302-1308
CrossRef136
J.-C. Lu, H. Tao, Y.-Q. Zhang, W.-W. Zha, P.-D. Qian, F. Li, K.-X. Xu. (2008) Extent of prophylactic postoperative radiotherapy after radical surgery of thoracic esophageal squamous cell carcinoma. Diseases of the Esophagus 21:6, 502-507
CrossRef137
Simon Ekman, Martin Dreilich, Johan Lennartsson, Bengt Wallner, Daniel Brattström, Magnus Sundbom, Michael Bergqvist. (2008) Esophageal cancer: current and emerging therapy modalities. Expert Review of Anticancer Therapy 8:9, 1433-1448
CrossRef138
Werner Hartwig, Oliver Strobel, Lutz Schneider, Thilo Hackert, Christine Hesse, Markus W. Büchler, Jens Werner. (2008) Fundus Rotation Gastroplasty vs. Kirschner-Akiyama Gastric Tube in Esophageal Resection: Comparison of Perioperative and Long-Term Results. World Journal of Surgery 32:8, 1695-1702
CrossRef139
G. F. Tillman, T. Pawlicki, A. C. Koong, K. A. Goodman. (2008) Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: a comparison of normal tissue radiation doses. Diseases of the Esophagus 21:5, 437-444
CrossRef140
Toni Lerut, Johnny Moons, Willy Coosemans, Herbert Decaluwé, Georges Decker, Paul De Leyn, Philippe Nafteux, Dirk Van Raemdonck. (2008) Multidisciplinary Treatment of Advanced Cancer of the Esophagus and Gastroesophageal Junction: A European Center's Approach. Surgical Oncology Clinics of North America 17:3, 485-502
CrossRef141
Feng‐Ming Hsu, Chia‐Chi Lin, Jang‐Ming Lee, Yih‐Leong Chang, Chih‐Hung Hsu, Yu‐Chieh Tsai, Yung‐Chie Lee, Jason Chia‐Hsien Cheng. (2008) Improved local control by surgery and paclitaxel‐based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non‐randomized study. Journal of Surgical Oncology 98:1, 34-41
CrossRef142
Min Kyoung Kim, Sung- Bae Kim, Jin Hee Ahn, Yong Hee Kim, Jong Hoon Kim, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Ho-Young Song, Ji Hoon Shin, Kyung-Ja Cho, Jin-Sook Ryu, Seung-Il Park. (2008) Treatment Outcome and Recursive Partitioning Analysis-Based Prognostic Factors in Patients With Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 71:3, 725-734
CrossRef143
Yixing Jiang, Eric T Kimchi, Alberto J Montero, Kevin F Staveley-O’Carroll, Jaffer A Ajani. (2008) Upper gastrointestinal tumors: current status and future perspectives. Expert Review of Anticancer Therapy 8:6, 975-991
CrossRef144
Harry H Yoon, Arlene A Forastiere. (2008) Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. Future Oncology 4:3, 413-425
CrossRef145
Nikhil I. Khushalani. (2008) Cancer of the Esophagus and Stomach. Mayo Clinic Proceedings 83:6, 712-722
CrossRef146
N. I. Khushalani. (2008) Cancer of the Esophagus and Stomach. Mayo Clinic Proceedings 83:6, 712-722
CrossRef147
James M. McLoughlin, Marcovalerio Melis, Erin M. Siegel, E. Michelle Dean, Jill M. Weber, Jeannie Chern, Melanie Elliott, Scott T. Kelley, Richard C. Karl. (2008) Are Patients with Esophageal Cancer Who Become PET Negative after Neoadjuvant Chemoradiation Free of Cancer?. Journal of the American College of Surgeons 206:5, 879-886
CrossRef148
S. Borghesi, M.A. Hawkins, D. Tait. (2008) Oesophagectomy after Definitive Chemoradiation in Patients with Locally Advanced Oesophageal Cancer. Clinical Oncology 20:3, 221-226
CrossRef149
Masaru Morita, Rintaro Yoshida, Keisuke Ikeda, Akinori Egashira, Eiji Oki, Noriaki Sadanaga, Yoshihiro Kakeji, Takeharu Yamanaka, Yoshihiko Maehara. (2008) Advances in esophageal cancer surgery in Japan: An analysis of 1000 consecutive patients treated at a single institute. Surgery 143:4, 499-508
CrossRef150
C.M. Gillham, N. Aherne, S. Rowley, J. Moore, D. Hollywood, K. O'Byrne, J.V. Reynolds. (2008) Quality of Life and Survival in Patients Treated with Radical Chemoradiation Alone for Oesophageal Cancer. Clinical Oncology 20:3, 227-233
CrossRef151
Vahide I. Ugur, Sakire P. Kara, Bulent Kucukplakci, Taciser Demirkasimoglu, Cem Misirlioglu, Aytul Ozgen, Yesim Elgin, Ergun Sanri, Kadri Altundag, Nadi Ozdamar. (2008) Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey. Medical Oncology 25:1, 63-68
CrossRef152
Silvia Gómez Senent, César Gómez Raposo, José María Segura Cabral. (2008) Cáncer de esófago. Medicina Clínica 130:11, 423-428
CrossRef153
John S. Moody, Stephen M. Sawrie, Kevin R. Kozak, John P. Plastaras, George Howard, James A. Bonner. (2008) Stage-Specific Survival Differences Associated with Postoperative Radiotherapy for Gastrointestinal Cancers. Journal of Gastrointestinal Cancer 39:1-4, 86-99
CrossRef154
Brian G. Czito, Darrel P. Cohen, Chris R. Kelsey, A. Craig Lockhart, Johanna C. Bendell, Christopher G. Willett, William P. Petros, Thomas A. D'Amico, Roxanne Truax, Herbert I. Hurwitz. (2008) A Phase I Study of UFT/Leucovorin, Carboplatin, and Paclitaxel in Combination With External Beam Radiation Therapy for Advanced Esophageal Carcinoma. International Journal of Radiation Oncology*Biology*Physics 70:4, 1066-1072
CrossRef155
Simon K. H. Wong, Philip W. Y. Chiu, S. F. Leung, K. Y. Cheung, Angus C. W. Chan, Alex C. M. Au-Yeung, James F. Griffith, Sydney S. C. Chung, Enders K. W. Ng. (2008) Concurrent Chemoradiotherapy or Endoscopic Stenting for Advanced Squamous Cell Carcinoma of Esophagus: A Case-Control Study. Annals of Surgical Oncology 15:2, 576-582
CrossRef156
Sun Young Lee, Hyoung Cheol Kwon, Heui Kwan Lee, Jung Soo Kim, Soo Geon Kim. (2008) Lymph Node Failure Pattern and Treatment Results of Esophageal Cancer Patients Treated with Definitive Radiotherapy. The Journal of the Korean Society for Therapeutic Radiology and Oncology 26:2, 77
CrossRef157
O Kyu Noh, Hyoung Uk Je, Sung Bae Kim, Gin Hyug Lee, Seung Il Park, Si Yeol Song, Sang-wook Lee, Seung Do Ahn, Eun Kyung Choi, Jong Hoon Kim. (2008) Results of Definitive Chemoradiotherapy for Unresectable Esophageal Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology 26:4, 195
CrossRef158
L. Schoot, E. A. P. M. Romme, M. J. Sangen, G. J. Creemers, G. Lijnschoten, O. J. Repelaer Driel, H. J. T. Rutten, G. A. P. Nieuwenhuijzen. (2008) A Highly Active and Tolerable Neoadjuvant Regimen Combining Paclitaxel, Carboplatin, 5-FU, and Radiation Therapy in Patients with Stage II and III Esophageal Cancer. Annals of Surgical Oncology 15:1, 88-95
CrossRef159
A. Adenis, C. Mariette, X. Mirabel, T. Sarrazin, E. Lartigau, J.P. Triboulet. (2008) Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer. Early termination of a phase I trial. European Journal of Surgical Oncology (EJSO) 34:1, 30-35
CrossRef160
M. A. Morgan, W. G. Lewis, T. D. L. Crosby, X. Escofet, S. A. Roberts, A. E. Brewster, T. J. Harvard, G. W. B. Clark. (2007) Prospective cohort comparison of neoadjuvant chemoradiotherapyversus chemotherapy in patients with oesophageal cancer. British Journal of Surgery 94:12, 1509-1514
CrossRef161
Hinrich A. Wieder, Katja Ott, Florian Lordick, Karen Becker, Alexander Stahl, Ken Herrmann, Ulrich Fink, Jörg Rüdiger Siewert, Markus Schwaiger, Wolfgang A. Weber. (2007) Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. European Journal of Nuclear Medicine and Molecular Imaging 34:12, 1925-1932
CrossRef162
Nabil P. Rizk, Venkatraman E. Seshan, Manjit S. Bains, David H. Ilson, Bruce D. Minsky, Laura Tang, Valerie W. Rusch. (2007) Prognostic Factors After Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus. Journal of Thoracic Oncology 2:12, 1117-1123
CrossRef163
Véronique Veuillez, Philippe Rougier, Jean-François Seitz. (2007) Multimodal treatment of oesophageal cancer. Best Practice & Research Clinical Gastroenterology 21:6, 947-963
CrossRef164
Chris R. Kelsey, Junzo P. Chino, Christopher G. Willett, Robert W. Clough, Herbert I. Hurwitz, Michael A. Morse, Johanna C. Bendell, Thomas A. D'Amico, Brian G. Czito. (2007) Paclitaxel-Based Chemoradiotherapy in the Treatment of Patients With Operable Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics 69:3, 770-776
CrossRef165
Takeshi Nonoshita, Tomonari Sasaki, Hideki Hirata, Yasushi Toh, Yoshiyuki Shioyama, Katsumasa Nakamura, Hiroshi Honda. (2007) High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer. Radiation Medicine 25:8, 373-377
CrossRef166
Yasumasa Kondoh, Kyoji Ogoshi, Hiroyasu Makuuchi, Makoto Shibuya. (2007) Effects of nonsteroidal antiandrogen agents on experimental esophageal carcinoma in rats. Esophagus 4:3, 111-115
CrossRef167
Joerg R. Siewert, Florian Lordick, Katja Ott, Hubert J. Stein, Wolfgang A. Weber, Karen Becker, Christian Peschel, Ulrich Fink, Markus Schwaiger. (2007) Induction Chemotherapy in Barrett Cancer. Annals of Surgery 246:4, 624-631
CrossRef168
Francesca Milano, Agnieszka M. Rygiel, Navtej Buttar, Jacques J. G. H. M. Bergman, Carine Sondermeijer, Jantine W. P. M. Baal, Anja Brinke, Martien Kapsenberg, S. Marieke Ham, Maikel P. Peppelenbosch, Kausilia K. Krishnadath. (2007) An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer. Cancer Immunology, Immunotherapy 56:12, 1967-1977
CrossRef169
F. Lordick, K. Ott, A. Novotny, C. Schuhmacher, J.R. Siewert. (2007) R1-Resektion in der Chirurgie des oberen Gastrointestinaltrakts. Der Chirurg 78:9, 792-801
CrossRef170
M. Schenck, F. Dorp, C. Boergermann, Y. Busch, A. Carpinteiro, B. Wilker, S. Keitsch, K.W. Schmid, M. Groneberg, M. Stuschke, H. Ruebben, E. Gulbins. (2007) Gründung einer Arbeitsgruppe „Lymphknotenmetastasierung“ am Westdeutschen Tumorzentrum (WTZE), Universitätsklinikum Essen. Der Urologe 46:9, 1257-1260
CrossRef171
Yi-Jen Chen, An Liu, Chunhui Han, Peter T. Tsai, Timothy E. Schultheiss, Richard D. Pezner, Nilesh Vora, Dean Lim, Stephen Shibata, Kemp H. Kernstine, Jeffrey Y.C. Wong. (2007) Helical Tomotherapy for Radiotherapy in Esophageal Cancer: A Preferred Plan With Better Conformal Target Coverage and More Homogeneous Dose Distribution. Medical Dosimetry 32:3, 166-171
CrossRef172
Marcelo Mamede, Paula Abreu-e-Lima, Maria Raquel Oliva, V??nia Nos??, Harvey Mamon, Victor H. Gerbaudo. (2007) FDG-PET/CT Tumor Segmentation-Derived Indices of Metabolic Activity to Assess Response to Neoadjuvant Therapy and Progression-Free Survival in Esophageal Cancer. American Journal of Clinical Oncology 30:4, 377-388
CrossRef173
H. TAKALA, J. SAARNIO, H. WIIK, Y. SOINI. (2007) Claudins 1, 3, 4, 5 and 7 in esophageal cancer: loss of claudin 3 and 4 expression is associated with metastatic behavior. APMIS 115:7, 838-847
CrossRef174
Zhongxing Liao, James D. Cox, Ritsuko Komaki. (2007) Radiochemotherapy of Esophageal Cancer. Journal of Thoracic Oncology 2:6, 553-568
CrossRef175
L. Walshe, S. Rowley, M. Coffey, D. Hollywood, M. J. Kennedy, C. Gillham, N. Ravi, J. V. Reynolds. (2007) Comparison of two fractionation regimens in the multimodal therapy of cancer of the esophagus. Diseases of the Esophagus 20:3, 217-224
CrossRef176
Min Kyoung Kim, Jin-Sook Ryu, Sung-Bae Kim, Jin Hee Ahn, Soo Young Kim, Seung-II Park, Yong Hee Kim, Ho Yong Song, Ji Hoon Shin, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Kyung-Ja Cho, Jong Hoon Kim. (2007) Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. European Journal of Cancer 43:9, 1385-1391
CrossRef177
J. C. Clifton, R. J. Finley, G. Gelfand, A. J. Graham, R. Inculet, R. Malthaner, L. Tan, J. Lim, J. Singer, C. Lovato. (2007) Development and validation of a disease-specific quality of life questionnaire (EQOL) for potentially curable patients with carcinoma of the esophagus. Diseases of the Esophagus 20:3, 191-201
CrossRef178
András Papp, László Cseke, Gábor Pavlovics, Róbert Farkas, Gábor Varga, Sándor Márton, László Pótó, Olga Ésik, Örs Péter Horváth. (2007) A preoperatív kemo-radioterápia hatása az előrehaladott felső és középső harmadi nyelőcső laphámrákok kezelésében. Magyar Sebészet (Hungarian Journal of Surgery) 60:3, 123-129
CrossRef179
Christophe Mariette, Guillaume Piessen, Jean-Pierre Triboulet. (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. The Lancet Oncology 8:6, 545-553
CrossRef180
Harry H. Yoon, Michael K. Gibson. (2007) Combined-modality therapy for esophageal and gastroesophageal junction cancers. Current Oncology Reports 9:3, 184-192
CrossRef181
John Vincent Reynolds, Cian Muldoon, Donal Hollywood, Narayanasamy Ravi, Suzanne Rowley, Ken O???Byrne, John Kennedy, Thomas J. Murphy. (2007) Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Annals of Surgery 245:5, 707-716
CrossRef182
Lawrence Kleinberg, Michael K Gibson, Arlene A Forastiere. (2007) Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nature Clinical Practice Oncology 4:5, 282-294
CrossRef183
Geoffrey Y. Ku, David H. Ilson. (2007) Esophageal Cancer: Adjuvant Therapy. The Cancer Journal 13:3, 162-167
CrossRef184
Andrew J. Graham, Fiona M. Shrive, William A. Ghali, Braden J. Manns, Sean C. Grondin, Richard J. Finley, Joanne Clifton. (2007) Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis. The Annals of Thoracic Surgery 83:4, 1257-1264
CrossRef185
David J. Adelstein, Thomas W. Rice, Lisa A. Rybicki, Jerrold P. Saxton, Gregory M. M. Videtic, Sudish C. Murthy, Gregory Zuccaro, John J. Vargo, John A. Dumot, Marjorie A. Carroll. (2007) A Phase II Trial of Accelerated Multimodality Therapy for Locoregionally Advanced Cancer of the Esophagus and Gastroesophageal Junction. American Journal of Clinical Oncology 30:2, 172-180
CrossRef186
R. Adams, M. Morgan, S. Mukherjee, A. Brewster, T. Maughan, D. Morrey, T. Havard, W. Lewis, G. Clark, S. Roberts, L. Vachtsevanos, J. Leong, R. Hardwick, D. Carey, T. Crosby. (2007) A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. European Journal of Surgical Oncology (EJSO) 33:3, 307-313
CrossRef187
Brian G. Czito, Chris R. Kelsey, Herbert I. Hurwitz, Chris G. Willett, Michael A. Morse, Gerard C. Blobe, Nishan H. Fernando, Thomas A. D’Amico, David H. Harpole, Wanda Honeycutt, Daohai Yu, Johanna C. Bendell. (2007) A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. International Journal of Radiation Oncology*Biology*Physics 67:4, 1002-1007
CrossRef188
Giovanni de Manzoni, Corrado Pedrazzani, Felice Pasini, Marco Bernini, Anna Maria Minicozzi, Simone Giacopuzzi, Antonio Grandinetti, Claudio Cordiano. (2007) Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. Journal of Surgical Oncology 95:3, 261-266
CrossRef189
Kalpaj Parekh, Mark D. Iannettoni. (2007) Complications of Esophageal Resection and Reconstruction. Seminars in Thoracic and Cardiovascular Surgery 19:1, 79-88
CrossRef190
Dong W. Kim, Charles D. Blanke, Huiyun Wu, Yu Shyr, Jordan Berlin, R. Daniel Beauchamp, Bapsi Chakravarthy. (2007) Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. International Journal of Radiation Oncology*Biology*Physics 67:2, 397-404
CrossRef191
Henry Wang, Janice Ryu, David Gandara, Richard J. Bold, Shiro Urayama, Michael Tanaka, Zelanna Goldberg, David Follette, Samir Narayan, Derick Lau. (2007) A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer. Journal of Thoracic Oncology153-157
CrossRef192
Bryan J. Schneider, Susan G. Urba. (2007) Preoperative Chemoradiation for the Treatment of Locoregional Esophageal Cancer: The Standard of Care?. Seminars in Radiation Oncology 17:1, 45-52
CrossRef193
David Tougeron, Frédéric Di Fiore, Hadji Hamidou, Olivier Rigal, Bernard Paillot, Pierre Michel. (2007) Response to Definitive Chemoradiotherapy and Survival in Patients with an Oesophageal Adenocarcinoma versus Squamous Cell Carcinoma: A Matched-Pair Analysis. Oncology 73:5-6, 328-334
CrossRef194
Chilukuri Srinivas, Sarbani Ghosh Laskar, R.C. Mistry, C.S. Pramesh, K.A. Dinshaw. (2007) Systematic overview of preoperative chemoradiation trials in esophageal cancer: In response to article by Ian Geh et al.. Radiotherapy and Oncology 82:1, 106-107
CrossRef195
Theodore S. Hong, Elizabeth M. Crowley, Joseph Killoran, Harvey J. Mamon. (2007) Considerations in Treatment Planning for Esophageal Cancer. Seminars in Radiation Oncology 17:1, 53-61
CrossRef196
Mohan Suntharalingam. (2007) Definitive Chemoradiation in the Management of Locally Advanced Esophageal Cancer. Seminars in Radiation Oncology 17:1, 22-28
CrossRef197
John F. Bruzzi, Stephen G. Swisher, Mylene T. Truong, Reginald F. Munden, Wayne L. Hofstetter, Homer A. Macapinlac, Arlene M. Correa, Osama Mawlawi, Jaffer A. Ajani, Ritsuko R. Komaki, Norio Fukami, Jeremy J. Erasmus. (2007) Detection of interval distant metastases. Cancer 109:1, 125-134
CrossRef198
Takashi KOBAYASHI, Masanori TERUYA, Hozumi TANAKA, Kaoru KOBAYASHI, Koji MORITA. (2007) EVALUATION OF NEOADJUVANT CHEMORADIOTHERAPY IN CLINICAL STAGE II AND III ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN A REGIONAL CENTER HOSPITAL. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 68:12, 2931-2939
CrossRef199
Tsung-Teh Wu, Lucian R. Chirieac, Susan C. Abraham, Alyssa M. Krasinskas, Huamin Wang, Asif Rashid, Arlene M. Correa, Wayne L. Hofstetter, Jaffer A. Ajani, Stephen G. Swisher. (2007) Excellent Interobserver Agreement on Grading the Extent of Residual Carcinoma After Preoperative Chemoradiation in Esophageal and Esophagogastric Junction Carcinoma: A Reliable Predictor for Patient Outcome. The American Journal of Surgical Pathology 31:1, 58-64
CrossRef200
Christopher Jackson, Naureen Starling, Yu Jo Chua, David Cunningham. (2007) Pharmacotherapy for Oesophagogastric Cancer. Drugs 67:17, 2539-2556
CrossRef201
Takashi Yoshioka, Masato Sakayori, Shunsuke Kato, Natsuko Chiba, Shukichi Miyazaki, Kenji Nemoto, Hiroyuki Shibata, Hideki Shimodaira, Kazunori Ohtsuka, Yuichi Kakudo, Yuh Sakata, Chikashi Ishioka. (2006) Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. International Journal of Clinical Oncology 11:6, 454-460
CrossRef202
S. Natsugoe, H. Okumura, M. Matsumoto, Y. Uchikado, T. Setoyama, N. Yokomakura, S. Ishigami, T. Owaki, T. Aikou. (2006) Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Diseases of the Esophagus 19:6, 468-472
CrossRef203
Ioannis Rouvelas, Wenyi Zeng, Mats Lindblad, Pernilla Viklund, Weimin Ye, Jesper Lagergren. (2006) Survival After Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophageal Cancer in a Population-based Study. World Journal of Surgery 30:12, 2182-2190
CrossRef204
Andrew M. Lowy, Irfan Firdaus, Debasish Roychowdhury, Kevin Redmond, John A. Howington, Jeffrey J. Sussman, Malek Safa, Syed A. Ahmad, Michael F. Reed, Patricia Rose, Laura James, Abdul Rahman Jazieh. (2006) A Phase II Study of Sequential Neoadjuvant Gemcitabine and Paclitaxel, Radiation Therapy With Cisplatin and 5-Fluorouracil and Surgery in Locally Advanced Esophageal Carcinoma. American Journal of Clinical Oncology 29:6, 555-561
CrossRef205
Gilles Cr??hange, Mathieu Bosset, Lorchel Fabrice, Jo??lle Buffet-Miny, Jean Luc Dumas, Mariette Mercier, Marc Puyraveau, Philippe Maingon, Jean Fran??ois Bosset. (2006) Tumor Volume as Outcome Determinant in Patients Treated With Chemoradiation for Locally Advanced Esophageal Cancer. American Journal of Clinical Oncology 29:6, 583-587
CrossRef206
C M Gillham, J A Lucey, M Keogan, G J Duffy, V Malik, A A Raouf, K O'Byrne, D Hollywood, C Muldoon, J V Reynolds. (2006) 18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. British Journal of Cancer 95:9, 1174-1179
CrossRef207
R. M. Hermann, O. Horstmann, F. Haller, C. Perske, H. Christiansen, A. Hille, H. Schmidberger, L. Füzesi. (2006) Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use?. Diseases of the Esophagus 19:5, 329-334
CrossRef208
Tatsushi Suwa, Yuko Kitagawa, Takahiro Sasaki, Tomoo Shatari, Masayoshi Sakuma, Masaki Kitajima. (2006) Release of band cells from the bone marrow is impaired by preoperative chemoradiation in patients with esophageal carcinoma: increased risk of postoperative pneumonia. Langenbeck's Archives of Surgery 391:5, 461-466
CrossRef209
C. Mariette, G. Piessen, A. Lamblin, X. Mirabel, A. Adenis, J. P. Triboulet. (2006) Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. British Journal of Surgery 93:9, 1077-1083
CrossRef210
John V. Reynolds, Narayanasamy Ravi, Donal Hollywood, M. John Kennedy, Suzanne Rowley, Aoife Ryan, Niall Hughes, Michael Carey, Patrick Byrne. (2006) Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. The Journal of Thoracic and Cardiovascular Surgery 132:3, 549-555
CrossRef211
M. MacGuill, E. Mulligan, N. Ravi, S. Rowley, P. J. Byrne, D. Hollywood, J. Kennedy, P. N. Keeling, J. V. Reynolds. (2006) Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. Diseases of the Esophagus 19:4, 273-276
CrossRef212
Gaelle Godiris-Petit, Nicolas Munoz-Bongrand, Isabelle Honigman, Pierre Cattan, Emile Sarfati. (2006) Minimally Invasive Esophagectomy for Cancer: Prospective Evaluation of Laparoscopic Gastric Mobilization. World Journal of Surgery 30:8, 1434-1440
CrossRef213
S SATO, Y KAJIYAMA, M SUGANO, Y IWANUMA, H SONOUE, T MATSUMOTO, M TSURUMARU. (2006) Alvocidib (Flavopiridol) suppresses tumor growth in SCID mice with human esophageal cancer xenografts without inducing apoptosis. Surgical Oncology 15:2, 107-113
CrossRef214
Frédéric Di Fiore, Stéphane Lecleire, Marie-Pierre Galais, Olivier Rigal, Brigitte Vié, Isabelle David, Hadji Hamidou, Bernard Paillot, Jacques-Henri Jacob, Pierre Michel. (2006) Impact of radiation schedule and chemotherapy duration in definitive chemoradiotherapy regimen for esophageal cancer. Gastroentérologie Clinique et Biologique 30:6-7, 845-851
CrossRef215
Ichinosuke Hyodo. (2006) Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue. Journal of Gastroenterology 41:5, 504-506
CrossRef216
M. R. Stephens, W. G. Lewis, A. E. Brewster, I. Lord, G. R. J. C. Blackshaw, I. Hodzovic, G. V. Thomas, S. A. Roberts, T. D. L. Crosby, C. Gent, M. C. Allison, K. Shute. (2006) Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Diseases of the Esophagus 19:3, 164-171
CrossRef217
E van Meerten, K Muller, H W Tilanus, P D Siersema, W M H Eijkenboom, H van Dekken, T C K Tran, A van der Gaast. (2006) Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. British Journal of Cancer 94:10, 1389-1394
CrossRef218
Björn L. D. M. Brücher, Karen Becker, Florian Lordick, Ulrich Fink, Mario Sarbia, Hubert Stein, Raymonde Busch, Frank Zimmermann, Michael Molls, Heinz Höfler, Jörg R. Siewert. (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106:10, 2119-2127
CrossRef219
S. Mukherjee, J. Abraham, A. Brewster, R. Hardwick, T. Havard, W. Lewis, C. Askill, J. Manson, G.T. Williams, S.A. Roberts, J. Court, T. Crosby. (2006) Pilot Study of Preoperative Combined Modality Treatment for Locally Advanced Operable Oesophageal Carcinoma: Toxicities and Long-term Outcome. Clinical Oncology 18:4, 338-344
CrossRef220
Thomas Ng, Thomas Dipetrillo, John Purviance, Howard Safran. (2006) Multimodality treatment of esophageal cancer: A review of the current status and future directions. Current Oncology Reports 8:3, 174-182
CrossRef221
Lorenzo E. Ferri, Simon Law, Kam-Ho Wong, Ka-Fai Kwok, John Wong. (2006) The Influence of Technical Complications on Postoperative Outcome and Survival After Esophagectomy. Annals of Surgical Oncology 13:4, 557-564
CrossRef222
Christoph Oehler, I. Frank Ciernik. (2006) Radiation therapy and combined modality treatment of gastrointestinal carcinomas. Cancer Treatment Reviews 32:2, 119-138
CrossRef223
Edward A. Levine, Michael R. Farmer, Paige Clark, Girish Mishra, Coty Ho, Kim R. Geisinger, Susan A. Melin, James Lovato, Tim Oaks, A William Blackstock. (2006) Predictive Value of 18-Fluoro-Deoxy-Glucose-Positron Emission Tomography (18F-FDG-PET) in the Identification of Responders to Chemoradiation Therapy for the Treatment of Locally Advanced Esophageal Cancer. Annals of Surgery 243:4, 472-478
CrossRef224
J. Zacherl, C. Neumayer, F. Langer. (2006) Esophageal cancer: International guidelines in interdisciplinary diagnosis and treatment. European Surgery 38:2, 79-88
CrossRef225
Christophe Mariette, Jean-Pierre Triboulet. (2006) Should Resectable Esophageal Cancer Be Resected?. Annals of Surgical Oncology 13:4, 447-449
CrossRef226
Feng-Ming (Spring) Kong, Lujun Zhao, James A. Hayman. (2006) The Role of Radiation Therapy in Thoracic Tumors. Hematology/Oncology Clinics of North America 20:2, 363-400
CrossRef227
Arthur Y. Hung, Christopher A. Canning, Kamal M. Patel, John M. Holland, Lisa A. Kachnic. (2006) Radiation Therapy for Gastrointestinal Cancer. Hematology/Oncology Clinics of North America 20:2, 287-320
CrossRef228
Yan Gu, Stephen G. Swisher, Jaffer A. Ajani, Arlene M. Correa, Wayne L. Hofstetter, Zhongxing Liao, Ritsuko R. Komaki, Asif Rashid, Stanley R. Hamilton, Tsung-Teh Wu. (2006) The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 106:5, 1017-1025
CrossRef229
Leonard R. Henry, Melvyn Goldberg, Walter Scott, Andre Konski, Neal J. Meropol, Gary Freedman, Louis M. Weiner, Perry Watts, Mary Beard, Susan McLaughlin, Jonathan D. Cheng. (2006) Induction Cisplatin and Paclitaxel Followed by Combination Chemoradiotherapy with 5-Fluorouracil, Cisplatin, and Paclitaxel Before Resection in Localized Esophageal Cancer: A Phase II Report. Annals of Surgical Oncology 13:2, 214-220
CrossRef230
Jason L Hornick, Francis A Farraye, Robert D Odze. (2006) Prevalence and Significance of Prominent Mucin Pools in the Esophagus Post Neoadjuvant Chemoradiotherapy for Barrett??s-Associated Adenocarcinoma. The American Journal of Surgical Pathology 30:1, 28-35
CrossRef231
Javier Valencia Julve, Vicente Alonso Orduña, Ricardo Escó Barón, Miriam López-Mata, Agustina Méndez Villamón. (2006) Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clinical and Translational Oncology 8:1, 22-30
CrossRef232
Michael C. Dobelbower, Suzanne M. Russo, Kevin P. Raisch, Leisa L. Seay, Lisa K. Clemons, Susan Suter, James Posey, James A. Bonner. (2006) Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anti-Cancer Drugs 17:1, 95-102
CrossRef233
J.Th.M. Plukker, H.L. van Westreenen. (2006) Staging in oesophageal cancer. Best Practice & Research Clinical Gastroenterology 20:5, 877-891
CrossRef234
Steven R. DeMeester. (2006) Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment. Annals of Surgical Oncology 13:1, 12-30
CrossRef235
M.M. Mooney. (2005) Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma. Journal of Surgical Oncology 92:3, 230-238
CrossRef236
Jean-Franois Bosset, F. Lorchel, G. Mantion, J. Buffet, G. Créhange, M. Bosset, L. Chaigneau, S. Servagi. (2005) Radiation and chemoradiation therapy for esophageal adenocarcinoma. Journal of Surgical Oncology 92:3, 239-245
CrossRef237
P. Tripp, H. K. Malhotra, M. Javle, A. Shaukat, R. Russo, S. Boer, M. Podgorsak, H. Nava, G. Y. Yang. (2005) Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Diseases of the Esophagus 18:6, 400-405
CrossRef238
Y. Nabeya, T. Ochiai, H. Matsubara, S. Okazumi, T. Shiratori, K. Shuto, T. Aoki, S. Miyazaki, Y. Gunji, T. Uno, H. Ito, H. Shimada. (2005) Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis. Diseases of the Esophagus 18:6, 388-397
CrossRef239
Pooja Rohatgi, Stephen G. Swisher, Arlene M. Correa, Tsung-T. Wu, Zhongxing Liao, Ritsuko Komaki, Garrett L. Walsh, Ara A. Vaporciyan, David C. Rice, Jack A. Roth, Jaffer A. Ajani. (2005) Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 104:11, 2365-2372
CrossRef240
Steven R. DeMeester. (2005) Endoscopic Mucosal Resection and Vagal-Sparing Esophagectomy for High-Grade Dysplasia and Adenocarcinoma of the Esophagus. Seminars in Thoracic and Cardiovascular Surgery 17:4, 320-325
CrossRef241
Ioannis Rouvelas, Wenyi Zeng, Mats Lindblad, Pernilla Viklund, Weimin Ye, Jesper Lagergren. (2005) Survival after surgery for oesophageal cancer: a population-based study. The Lancet Oncology 6:11, 864-870
CrossRef242
Paul M. Schneider, Stephan E. Baldus, Ralf Metzger, Martin Kocher, Rudolf Bongartz, Elfriede Bollschweiler, Hartmut Schaefer, Juergen Thiele, Hans P. Dienes, Rolf P. Mueller, Arnulf H. Hoelscher. (2005) Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer. Annals of Surgery 242:5, 684-692
CrossRef243
F. Lordick. (2005) Neoadjuvante Therapie von Plattenepithelkarzinomen des Ösophagus. Der Chirurg 76:11, 1025-1032
CrossRef244
Bryan H Burmeister, B Mark Smithers. (2005) Neoadjuvant chemoradiotherapy in resectable oesophageal cancer – Authors' reply. The Lancet Oncology 6:11, 825-826
CrossRef245
Jason J. Schrager, John L. Tarpley, Walter E. Smalley, Mary T. Austin, A. Scott Pearson. (2005) Endoscopic ultrasound: impact on survival in patients with esophageal cancer. The American Journal of Surgery 190:5, 682-686
CrossRef246
H. Igaki, H. Kato, Y. Tachimori, Y. Nakanishi, T. Shimoda. (2005) Surgery for clinical T3 carcinomas of the upper thoracic oesophagus and the need for new strategies. British Journal of Surgery 92:10, 1235-1240
CrossRef247
Jeeyun Lee, Kyoung-Eun Lee, Young-Hyuck Im, Won Ki Kang, Keunchil Park, Kwhanmien Kim, Young Mog Shim. (2005) Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma. The Annals of Thoracic Surgery 80:4, 1170-1175
CrossRef248
Giovanni de Manzoni, Corrado Pedrazzani, Ernesto Laterza, Felice Pasini, Antonio Grandinetti, Marco Bernini, Andrea Ruzzenente, Germana Zerman, Anna Tomezzoli, Claudio Cordiano. (2005) Induction Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Impact of Increased Dosage on Long-Term Results. The Annals of Thoracic Surgery 80:4, 1176-1183
CrossRef249
Hiroyuki Kato, Minoru Fukuchi, Tatsuya Miyazaki, Masanobu Nakajima, Hitoshi Kimura, Ahmad Faried, Makoto Sohda, Yasuyuki Fukai, Norihiro Masuda, Ryokuhei Manda, Hitoshi Ojima, Katsuhiko Tsukada, Noboru Oriuchi, Keigo Endo, Hiroyuki Kuwano. (2005) Positron emission tomography in esophageal cancer. Esophagus 2:3, 111-121
CrossRef250
C. R. Thomas. (2005) Current and ongoing progress in the therapy for resectable esophageal cancer. Diseases of the Esophagus 18:4, 211-214
CrossRef251
P. Guillem, J. P. Triboulet. (2005) Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Diseases of the Esophagus 18:3, 146-150
CrossRef252
Gauri Varadhachary, Jaffer A Ajani. (2005) Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Review of Anticancer Therapy 5:4, 719-725
CrossRef253
Robert James Cerfolio, Ayesha S. Bryant, Buddhiwardhan Ohja, Alfred A. Bartolucci, Mohamad A. Eloubeidi. (2005) The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. The Journal of Thoracic and Cardiovascular Surgery 129:6, 1232-1241
CrossRef254
Nasser Altorki. (2005) En-bloc Esophagectomy—The Three-Field Dissection. Surgical Clinics of North America 85:3, 611-619
CrossRef255
Ziv Gamliel, Mark J. Krasna. (2005) Multimodality Treatment of Esophageal Cancer. Surgical Clinics of North America 85:3, 621-630
CrossRef256
Kenneth K. Wang, Michel Wongkeesong, Navtej S. Buttar. (2005) American Gastroenterological Association Technical Review on the Role of the Gastroenterologist in the Management of Esophageal Carcinoma. Gastroenterology 128:5, 1471-1505
CrossRef257
François Lacaine. (2005) Evidence-based Medicine in Surgical Decision Making. World Journal of Surgery 29:5, 588-591
CrossRef258
Jane M. Blazeby, Emma Sanford, Stephen J. Falk, Derek Alderson, Jenny L. Donovan. (2005) Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 103:9, 1791-1799
CrossRef259
Robert J. Korst, Nasser K. Altorki. (2005) Imaging for Esophageal Tumors. Radiologic Clinics of North America 43:3, 611-619
CrossRef260
Banke Agarwal, Stephen G. Swisher, Jaffer Ajani, Kaitlyn Kelly, Ritsuko R. Komaki, Emad Abu-Hamda, Arlene M. Correa, Jack A. Roth. (2005) Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic Gastroesophageal Reflux. The Annals of Thoracic Surgery 79:5, 1716-1723
CrossRef261
Lucian R. Chirieac, Stephen G. Swisher, Jaffer A. Ajani, Ritsuko R. Komaki, Arlene M. Correa, Jeffrey S. Morris, Jack A. Roth, Asif Rashid, Stanley R. Hamilton, Tsung-Teh Wu. (2005) Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103:7, 1347-1355
CrossRef262
Masahiko Yano, Takushi Yasuda, Hiroshi Miyata, Yoshiyuki Fujiwara, Shuji Takiguchi, Morito Monden. (2005) Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus. Journal of Surgical Oncology 89:4, 244-250
CrossRef263
Tawee Tanvetyanon, Joseph I. Clark, Steve C. Campbell, Simon S. Lo. (2005) Neoadjuvant Therapy: An Emerging Concept in Oncology. Southern Medical Journal 98:3, 338-344
CrossRef264
J. DeWitt, K. Kesler, J. A. Brooks, J. LeBlanc, L. McHenry, K. McGreevy, S. Sherman. (2005) Endoscopic ultrasound for esophageal and gastroesophageal junction cancer: Impact of increased use of primary neoadjuvant therapy on preoperative locoregional staging accuracy. Diseases of the Esophagus 18:1, 21-27
CrossRef265
Sarah E. Greer, Philip P. Goodney, John E. Sutton, John D. Birkmeyer. (2005) Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis. Surgery 137:2, 172-177
CrossRef266
A. Gómez España, R. Serrano Blanch, E. Aranda Aguilar. (2005) Cáncer de esófago. Medicine - Programa de Formación Médica Continuada Acreditado 9:25, 1605-1612
CrossRef267
David C. Rice, Arlene M. Correa, Ara A. Vaporciyan, Nidhi Sodhi, W. Roy Smythe, Stephen G. Swisher, Garrett L. Walsh, Joe B. Putnam, Ritsuko Komaki, Jaffer A. Ajani, Jack A. Roth. (2005) Preoperative Chemoradiotherapy Prior to Esophagectomy in Elderly Patients is Not Associated With Increased Morbidity. The Annals of Thoracic Surgery 79:2, 391-397
CrossRef268
Takahiro MORI, Shukichi MIYAZAKI, Go MIYATA, Ko SUGAWARA, Ko ONODERA, Hirofumi ICHIKAWA, Takashi KAMEI, Hiroshi KIKUCHI, Rikiya KANBA, Susumu SATOMI, Tatsuya TAKAHASHI. (2005) Preoperative Radiation Therapy is an Independent and Strong Risk Factor for Late Non-cancer Death after Esophagectomy. Interdisciplinary Information Sciences 11:2, 141-147
CrossRef269
Axel Kleespie, Christiane J. Bruns, Karl-Walter Jauch. (2005) Clinical Significance of VEGF-A, -C and -D Expression in Esophageal Malignancies. Onkologie 28:5, 281-288
CrossRef270
Michael Stahl, Hansjochen Wilke, Martin Stuschke, Martin K. Walz, Ulrich Fink, Michael Molls, J. R
diger Siewert, Michael Schroeder, Hans-Bruno Makoski, Ulrich Schmidt, Siegfried Seeber, Udo Vanhoefer. (2005) Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. Journal of Cancer Research and Clinical Oncology 131:1, 67-72
CrossRef271
Nicolas Plaisant, Pierre Senesse, David Azria, Claire Lemanski, Marc Ychou, Francois Quenet, Bernard Saint-Aubert, Philippe Rouanet. (2005) Surgery for Esophageal Cancer after Concomitant Radiochemotherapy: Oncologic and Functional Results. World Journal of Surgery 29:1, 32-38
CrossRef272
Sang-Hee Cho, Ik-Joo Chung, Sang-Yun Song, Deok-Hwan Yang, Jeong-Rae Byun, Yeo-Kyeoung Kim, Je-Jung Lee, Kook-Joo Na, Hyeoung-Joon Kim. (2005) Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer. Journal of Korean Medical Science 20:4, 618
CrossRef273
T. Nakamura, K. Hayashi, M. Ota, H. Ide, K. Takasaki, M. Mitsuhashi. (2004) Expression of p21Waf1/Cip1 predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Diseases of the Esophagus 17:4, 315-321
CrossRef274
Steven K. Seung, John W. Smith, John Molendyk, Stephen B. Bader, Michael Phillips, James Regan, Jeannie Louie, Edward Soo, Mark Seligman, Janet Ruzich, Laurie Skokan, Helen J. Ross. (2004) Selective dose escalation of chemoradiotherapy for esophageal cancer: Role of treatment intensification. Seminars in Oncology 31, 13-19
CrossRef275
A. Genio, G. Rossetti, V. Napolitano, V. Maffettone, A. Renzi, L. Brusciano, G. Russo, G. Genio. (2004) Laparoscopic esophagectomy in the palliative treatment of advanced esophageal cancer after radiochemotherapy. Surgical Endoscopy 18:12, 1789-1794
CrossRef276
Frank C.-F. Lin, Amy E. Durkin, Mark K. Ferguson. (2004) Induction Therapy Does Not Increase Surgical Morbidity After Esophagectomy for Cancer. The Annals of Thoracic Surgery 78:5, 1783-1789
CrossRef277
M. Stuschke, M. Sarbia. (2004) Neoadjuvante Radiochemotherapie und Responsepr
CrossRef278
B.L.D.M. Brücher, H.J. Stein, F. Zimmermann, M. Werner, M. Sarbia, R. Busch, H.J. Dittler, M. Molls, U. Fink, J.R. Siewert. (2004) Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. European Journal of Surgical Oncology (EJSO) 30:9, 963-971
CrossRef279
C. Mariette, G. Piessen, J.M. Balon, I. Van Seuningen, J.P. Triboulet. (2004) Surgery alone in the curative treatment of localised oesophageal carcinoma. European Journal of Surgical Oncology (EJSO) 30:8, 869-876
CrossRef280
Tsutomu Nakamura, Kazuhiko Hayashi, Masaho Ota, Reiki Eguchi, Hiroko Ide, Ken Takasaki, Norio Mitsuhashi. (2004) Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. The American Journal of Surgery 188:3, 261-266
CrossRef281
J. A. Harvey, J. R. Bessell, E. Beller, J. Thomas, D. C. Gotley, B. H. Burmeister, E. T. Walpole, D. B. Thomson, I. Martin, L. Doyle, E. Burmeister, B. M. Smithers. (2004) Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Diseases of the Esophagus 17:3, 260-265
CrossRef282
CrossRef283
Jose G Guillem, Harvey G Moore, Timothy Akhurst, David S Klimstra, Leyo Ruo, Madhu Mazumdar, Bruce D Minsky, Leonard Saltz, W Douglas Wong, Steven Larson. (2004) Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer1 1No competing interests declared.. Journal of the American College of Surgeons 199:1, 1-7
CrossRef284
Jian Hu, Renyuan Li, Li Sun, Yiming Ni. (2004) Influence of esophageal carcinoma operations on gastroesophageal reflux. The Annals of Thoracic Surgery 78:1, 298-302
CrossRef285
R. Iyer, N. Wilkinson, T. Demmy, M. Javle. (2004) Controversies in the Multimodality Management of Locally Advanced Esophageal Cancer: Evidence-Based Review of Surgery Alone and Combined-Modality Therapy. Annals of Surgical Oncology 11:7, 665-673
CrossRef286
Banke Agarwal, Stephen Swisher, Jaffer Ajani, Kaitlyn Kelly, Christina Fanning, Ritsuko R. Komaki, Joe B. Putnam, Emad Abu-Hamda, Kimber L. Molke, Garrett L. Walsh, Arlene M. Correa, Linus Ho, Zhongxing Liao, Patrick M. Lynch, David C. Rice, W. Roy Smythe, Craig W. Stevens, Ara A. Vaporciyan, James Yao, Jack A. Roth. (2004) Endoscopic Ultrasound after Preoperative Chemoradiation Can Help Identify Patients Who Benefit Maximally after Surgical Esophageal Resection. The American Journal of Gastroenterology 99:7, 1258-1266
CrossRef287
Jaffer A. Ajani, Garrett Walsh, Ritsuko Komaki, Jeff Morris, Stephen G. Swisher, Joe B. Putnam, Patrick M. Lynch, Tsung-Teh Wu, Roy Smythe, Ara Vaporciyan, Josephine Faust, Deborah S. Cohen, Rebecca Nivers, Jack A. Roth. (2004) Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100:11, 2347-2354
CrossRef288
A. Shaukat, A. Mortazavi, T. Demmy, H. Nava, N. Wilkinson, G. Yang, J. Kepner, M. Javle. (2004) Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients?. Diseases of the Esophagus 17:2, 129-135
CrossRef289
I Brink, M Hentschel, T.A Bley, A Walch, M Mix, M Kleimaier, E Moser, A Imdahl. (2004) Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. European Journal of Surgical Oncology (EJSO) 30:5, 544-550
CrossRef290
Q. Yang, K. R. Cleary, J. C. Yao, S. G. Swisher, J. A. Roth, P. M. Lynch, R. Komaki, J. A. Ajani, A. Rashid, S. R. Hamilton, T.-T. Wu. (2004) Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Diseases of the Esophagus 17:1, 38-43
CrossRef291
G. N. J. Tytgat, H. Bartelink, R. Bernards, G. Giaccone, J. J. B. van Lanschot, G. J. A. Offerhaus, G. J. Peters. (2004) Cancer of the esophagus and gastric cardia: recent advances*. Diseases of the Esophagus 17:1, 10-26
CrossRef292
GAVIN C HAREWOOD, K SHIVA KUMAR. (2004) Assessment of clinical impact of endoscopic ultrasound on esophageal cancer. Journal of Gastroenterology and Hepatology 19:4, 433-439
CrossRef293
Vinay M Tak, Keith S Naunheim. (2004) Current status of multimodality therapy for esophageal carcinoma. Journal of Surgical Research 117:1, 22-29
CrossRef294
Paul Ryan, Seán McCarthy, Jacquie Kelly, J.Kevin Collins, Colum Dunne, Liam Grogan, Oscar Breathnach, Fergus Shanahan, P.Declan Carey, Thomas N. Walsh, Gerald C. O’Sullivan. (2004) Prevalence of bone marrow micrometastases in esophagogastric cancer patients with and without neoadjuvant chemoradiotherapy. Journal of Surgical Research 117:1, 121-126
CrossRef295
Peter Naughton, Thomas N Walsh. (2004) Multimodality therapy for cancers of the esophagus and gastric cardia. Expert Review of Anticancer Therapy 4:1, 141-150
CrossRef296
SIMON LAW, JOHN WONG. (2004) Therapeutic options for esophageal cancer. Journal of Gastroenterology and Hepatology 19:1, 4-12
CrossRef297
Paul M Harari, Mark A Ritter, Daniel G Petereit, Minesh P Mehta. (2004) Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Current Problems in Cancer 28:1, 7-40
CrossRef298
Andreas Imdahl, Ulrich Schöffel, Günther Ruf. (2004) Impact of neoadjuvant therapy of perioperative morbidity in patients with esophageal cancer. The American Journal of Surgery 187:1, 64-68
CrossRef299
Sanjay Sharma. (2004) Radical Esophagectomy for Carcinoma Esophagus-Is It Essential?. Nihon Kikan Shokudoka Gakkai Kaiho 55:2, 92-103
CrossRef300
Enzinger, Peter C., Mayer, Robert J., . (2003) Esophageal Cancer. New England Journal of Medicine 349:23, 2241-2252
Full Text301
J Balart, J Balmaña, X Rius, R Salazar, M Gallen, S Navarro, A Arcusa, E Gallardo, J Brunet. (2003) Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality. European Journal of Surgical Oncology (EJSO) 29:10, 884-889
CrossRef302
Bruno Walther, Jan Johansson, Folke Johnsson, Christer Staël von Holstein, Thomas Zilling. (2003) Cervical or Thoracic Anastomosis After Esophageal Resection and Gastric Tube Reconstruction. Annals of Surgery 238:6, 803-814
CrossRef303
David H Ilson. (2003) Oesophageal cancer: new developments in systemic therapy. Cancer Treatment Reviews 29:6, 525-532
CrossRef304
Susan G. Urba, Mark B. Orringer, Mark Ianettonni, James A. Hayman, Hayasaka Satoru. (2003) Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98:10, 2177-2183
CrossRef305
Thomas W Rice, David J Adelstein, Mark A Chidel, Lisa A Rybicki, Malcolm M DeCamp, Sudish C Murthy, Eugene H Blackstone. (2003) Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. The Journal of Thoracic and Cardiovascular Surgery 126:5, 1590-1596
CrossRef306
R.S Keresztes, J.L Port, M.W Pasmantier, R.J Korst, N.K Altorki. (2003) Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. The Journal of Thoracic and Cardiovascular Surgery 126:5, 1603-1608
CrossRef307
Sibyl E. Anderson, Bruce D. Minsky, Manjit Bains, David P. Kelsen, David H. Ilson. (2003) Combined modality therapy in esophageal cancer: The Memorial experience. Seminars in Surgical Oncology 21:4, 228-232
CrossRef308
Mikihito Nakamori, Makoto Iwahashi, Masaki Nakamura, Hiroki Yamaue. (2003) Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma. Journal of Surgical Oncology 84:1, 10-16
CrossRef309
M Tachibana, H Yoshimura, S Kinugasa, M Shibakita, D.K Dhar, S Ueda, T Fujii, N Nagasue. (2003) Postoperative chemotherapy vs. chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. European Journal of Surgical Oncology (EJSO) 29:7, 580-587
CrossRef310
Gregory D Leonard, John A McCaffrey, Michael Maher. (2003) Optimal therapy for oesophageal cancer. Cancer Treatment Reviews 29:4, 275-282
CrossRef311
Peter C Wu, Mitchell C Posner. (2003) The role of surgery in the management of oesophageal cancer. The Lancet Oncology 4:8, 481-488
CrossRef312
Michael K. Gibson, Arlene A. Forastiere. (2003) Combined-Modality Therapy for Esophageal Cancer. The Cancer Journal 9:4, 238-240
CrossRef313
Anthony Watson. (2003) Diagnosis and therapy for advanced esophageal cancer. Current Opinion in Gastroenterology 19:4, 400-405
CrossRef314
Anthony A. Meluch, F. Anthony Greco, James R. Gray, Melodie Thomas, Valerie M. Sutton, J. Lucian Davis, Leonard A. Kalman, Don W. Shaffer, Kathleen Yost, David A. Rinaldi, John D. Hainsworth. (2003) Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer. The Cancer Journal 9:4, 251-260
CrossRef315
B Visser. (2003) Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal. Surgical Oncology 12:1, 1-7
CrossRef316
Christophe Mariette, Laetitia Finzi, Sylvain Fabre, Jean-Michel Balon, Isabelle Van Seuningen, Jean-Pierre J Triboulet. (2003) Factors predictive of complete resection of operable esophageal cancer: a prospective study. The Annals of Thoracic Surgery 75:6, 1720-1726
CrossRef317
J. D. Urschel, S. Ashiku, R. Thurer, F. W. Sellke. (2003) Salvage or planned esophagectomy after chemoradiation therapy for locally advanced esophageal cancer - a review. Diseases of the Esophagus 16:2, 60-65
CrossRef318
Kulwinder S. Dua. (2003) New approach to malignant strictures of the esophagus. Current Gastroenterology Reports 5:3, 198-205
CrossRef319
Dennis Blom. (2003) Surgical management of esophageal malignancy. Current Gastroenterology Reports 5:3, 192-197
CrossRef320
John D Urschel, Hari Vasan. (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. The American Journal of Surgery 185:6, 538-543
CrossRef321
Alexander M. Yeh, William M. Mendenhall, Christopher G. Morris, Robert A. Zlotecki, Rodwige J. Desnoyers, Stephen B. Vogel. (2003) Factors predictive of survival for esophageal carcinoma treated with preoperative radiotherapy with or without chemotherapy followed by surgery. Journal of Surgical Oncology 83:1, 14-23
CrossRef322
J Harney, K Goodchild, H Phillips, R Glynne-Jones, P.J Hoskin, M.I Saunders. (2003) A Phase I/II Study of CHARTWEL with Concurrent Chemotherapy in Locally Advanced, Inoperable Carcinoma of the Oesophagus. Clinical Oncology 15:3, 109-114
CrossRef323
S Mukherjee, D Aston, M Minett, A.E Brewster, T.D.L Crosby. (2003) The Significance of Cardiac Doses Received During Chemoradiation of Oesophageal and Gastro–oesophageal Junctional Cancers. Clinical Oncology 15:3, 115-120
CrossRef324
J.W Denham, A Steigler, J Kilmurray, C Wratten, B Burmeister, D.S Lamb, D Joseph, G Delaney, D Christie, G Jamieson, B.M Smithers, S Ackland, E Walpole. (2003) Relapse Patterns after Chemo-radiation for Carcinoma of the Oesophagus. Clinical Oncology 15:3, 98-108
CrossRef325
Arnaud D. Roth. (2003) Curative treatment of gastric cancer: towards a multidisciplinary approach?. Critical Reviews in Oncology/Hematology 46:1, 59-100
CrossRef326
Christophe Mariette, Jean-Michel Balon, Guillaune Piessen, Sylvain Fabre, Isabelle Van Seuningen, Jean-Pierre Triboulet. (2003) Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 97:7, 1616-1623
CrossRef327
(2003) Surgical Treatment of Esophageal Cancer. New England Journal of Medicine 348:12, 1177-1179
Full Text328
P. Guillem, S. Fabre, C. Mariette, J.P. Triboulet. (2003) Surgery after induction chemoradiotherapy for oesophageal cancer. European Journal of Surgical Oncology (EJSO) 29:2, 158-165
CrossRef329
Ch. Haddad, F. Prat, Françoise Lefebvre, A. Amichi, P. Laugier, Semia Zidi, G. Pelletier, J. Fritsch, Geneviève Berger, Catherine Buffet. (2003) Caractérisation des ganglions lymphatiques péridigestifs par échoendoscopie: intérêt de l’imagerie paramétrique et analyse quantitative. Acta Endoscopica 33:1, 127-137
CrossRef330
Stephen H Bailey, David A Bull, David H Harpole, Jeffrey J Rentz, Leigh A Neumayer, Theodore N Pappas, Jennifer Daley, William G Henderson, Barbara Krasnicka, Shukri F Khuri. (2003) Outcomes after esophagectomy: a ten-year prospective cohort. The Annals of Thoracic Surgery 75:1, 217-222
CrossRef331
G. Terrosu, C. Cedolini, V. Bresadola, U. Baccarani, A. Uzzau, M. Signor, S. Fongione, A. Buffoli, A. Iop, E. Vigevani, C. Sacco, G. Cartei, F. Bresadola. (2003) Preoperative chemoradiotherapy in cancer of the thoracic esophagus. Diseases of the Esophagus 16:1, 9-16
CrossRef332
Simon Law, Dora L.W. Kwong, Ka-Fai Kwok, Kam-Ho Wong, Kent-Man Chu, Jonathan S. T. Sham, John Wong. (2003) Improvement in Treatment Results and Long-Term Survival of Patients With Esophageal Cancer. Transactions of the ... Meeting of the American Surgical Association 121, 33-42
CrossRef333
Jo Ann Brooks, Kenneth A. Kesler, Cynthia S. Johnson, Donato Ciaccia, John W. Brown. (2002) Prospective analysis of quality of life after surgical resection for esophageal cancer: Preliminary results. Journal of Surgical Oncology 81:4, 185-194
CrossRef334
Carol A. Sherman, Andrew T. Turrisi, Michael B. Wallace, Carolyn E. Reed. (2002) Locally advanced esophageal cancer. Current Treatment Options in Oncology 3:6, 475-485
CrossRef335
Jean-François Bosset, Mariette Mercier, Jean-Pierre Triboulet, Thierry Conroy, Jean-François Seitz. (2002) Surgical resection with and without chemotherapy in oesophageal cancer. The Lancet 360:9340, 1173-1174
CrossRef336
J. F. Bosset, F. Lorchel, G. Mantion. (2002) Neoadjuvant treatment of early stage squamous cell carcinoma of the esophagus*. Diseases of the Esophagus 15:2, 117-120
CrossRef337
Wayne Hofstetter, Stephen G. Swisher, Arlene M. Correa, Kenneth Hess, Joe B. Putnam, Jaffer A. Ajani, Marcelo Dolormente, Rhodette Francisco, Ritsuko R. Komaki, Axbal Lara, Faye Martin, David C. Rice, Arcenio J. Sarabia, W. Roy Smythe, Ara A. Vaporciyan, Garrett L. Walsh, Jack A. Roth. (2002) Treatment Outcomes of Resected Esophageal Cancer. Annals of Surgery 236:3, 376-385
CrossRef338
T. N. Walsh, M. Grennell, S. Mansoor, A. Kelly. (2002) Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival*. Diseases of the Esophagus 15:2, 121-124
CrossRef339
Dennis Blom, Jeffrey H. Peters, Tom R. DeMeester. (2002) Controversies in the current therapy of carcinoma of the esophagus1 1No competing interests declared.. Journal of the American College of Surgeons 195:2, 241-250
CrossRef340
A. C. W. Chan, D. W. H. Lee, J. F. Griffith, S. F. Leung, Y. H. Lam, C. C. H. Lam, J. Y. W. Lau, E. K. W. Ng, S. C. S. Chung. (2002) The clinical efficacy of neoadjuvant chemotherapy in squamous esophageal cancer: A prospective nonrandomized study of pulse and continuous-infusion regimens with cisplatin and 5-fluorouracil. Annals of Surgical Oncology 9:7, 617-624
CrossRef341
Yael Refaely, Mark J Krasna. (2002) Multimodality therapy for esophageal cancer. Surgical Clinics of North America 82:4, 729-746
CrossRef342
John R Doty, Jorge D Salazar, Arlene A Forastiere, Elisabeth I Heath, Lawrence Kleinberg, Richard F Heitmiller. (2002) Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy. The Annals of Thoracic Surgery 74:1, 227-231
CrossRef343
Martin Sundel
CrossRef344
Robert C. G. Martin, Murray F. Brennan, David P. Jaques. (2002) Quality of Complication Reporting in the Surgical Literature. Annals of Surgery 235:6, 803-813
CrossRef345
David H. Ilson. (2002) New developments in the treatment of esophageal cancer. Current Oncology Reports 4:3, 213-221
CrossRef346
Wolfgang Schröder, Stephan E. Baldus, Stefan P. Mönig, Tobias K. E. Beckurts, Hans P. Dienes, Arnulf H. Hölscher. (2002) Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: Histomorphologic analysis. World Journal of Surgery 26:5, 584-587
CrossRef347
Taofeek Owonikoko, MD, Martin Rees, MD, Helmut E. Gabbert, MD, Mario Sarbia, MD. (2002) Intratumoral Genetic Heterogeneity in Barrett Adenocarcinoma. American Journal of Clinical Pathology 117:4, 558-566
CrossRef348
Simon Law, John Wong. (2002) Changing disease burden and management issues for esophageal cancer in the Asia-Pacific region. Journal of Gastroenterology and Hepatology 17:4, 374-381
CrossRef349
M. Churn, B. Jones, A. Sun Myint. (2002) Radical Radiotherapy Incorporating a Brachytherapy Boost for the Treatment of Carcinoma of the Thoracic Oesophagus: Results from a Cohort of Patients and Review of the Literature. Clinical Oncology 14:2, 117-122
CrossRef350
John D Urschel, Hari Vasan, Chris J Blewett. (2002) A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. The American Journal of Surgery 183:3, 274-279
CrossRef351
John W.C Entwistle, Melvyn Goldberg. (2002) Multimodality therapy for resectable cancer of the thoracic esophagus. The Annals of Thoracic Surgery 73:3, 1009-1015
CrossRef352
H Shimada, T Hoshino, S Okazumi, H Matsubara, Y Funami, Y Nabeya, H Hayashi, A Takeda, T Shiratori, T Uno, H Ito, T Ochiai. (2002) Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. British Journal of Cancer 86:4, 552-557
CrossRef353
P. H. Lukas, U. Fink. (2002) Multimodality Treatment for Oesophageal Cancer. European Surgery-Acta Chirurgica Austriaca 34:1, 27-28
CrossRef354
THOMAS N WALSH, MARK GRANNELL, SHABAZ MANSOOR. (2002) Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer. Journal of Gastroenterology and Hepatology 17, S172-S175
CrossRef355
Paolo Bidoli, Emilio Bajetta, Simonetta C. Stani, Daniela De Candis, Armando Santoro, Maurizio Valente, Roberto Zucali, Pinuccia Valagussa, Gianni Ravasi, Gianni Bonadonna. (2002) Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer 94:2, 352-361
CrossRef356
Richard M. Gore, Vahid Yaghmai. 2002. Esophageal Cancer. , 359-390.
CrossRef357
David H. Ilson, David Kelsen. 2002. Esophageal Cancer: Treatment. , 169-177.
CrossRef358
Stephen G Swisher, Paula Wynn, Joe B Putnam, Melinda B Mosheim, Arlene M Correa, Ritsuko R Komaki, Jaffer A Ajani, W.Roy Smythe, Ara A Vaporciyan, Jack A Roth, Garrett L Walsh. (2002) Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. The Journal of Thoracic and Cardiovascular Surgery 123:1, 175-183
CrossRef359
Janusz A Jankowski, Mark R Anderson. (2001) The treatment, management and prevention of oesophageal cancer. Expert Opinion on Biological Therapy 1:6, 1017-1028
CrossRef360
Shigenao Nagasawa, Masahiko Onda, Koji Sasajima, Hiroshi Makino, Kiyohiko Yamashita, Kaiyo Takubo, Masao Miyashita. (2001) Cyclin D1 overexpression as a prognostic factor in patients with esophageal carcinoma. Journal of Surgical Oncology 78:3, 208-214
CrossRef361
T Lerut. (2001) Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surgical Oncology 10:3, 113-122
CrossRef362
J Blazeby. (2001) Measurement of outcome. Surgical Oncology 10:3, 127-133
CrossRef363
Jeffrey A. Hagen, Steven R. DeMeester, Jeffrey H. Peters, Para Chandrasoma, Tom R. DeMeester. (2001) Curative Resection for Esophageal Adenocarcinoma. Annals of Surgery 234:4, 520-531
CrossRef364
A.P. Chilton, J. Jankowski. (2001) Squamous carcinoma oesophagus: continuing to challenge. Digestive and Liver Disease 33:7, 528-530
CrossRef365
R. Chan, S. Morrill, D. Freeman, M. Colman, J. Zwischenberger. (2001) Bi-modality (chemo-radiation) versus tri-modality (chemo-radiation followed by surgery) treatment for carcinoma of the esophagus. Diseases of the Esophagus 14:3-4, 202-207
CrossRef366
Thomas A Aloia, David H Harpole, Carolyn E Reed, Carmen Allegra, Mary-Beth H Moore, James E Herndon, Thomas A D’Amico. (2001) Tumor marker expression is predictive of survival in patients with esophageal cancer. The Annals of Thoracic Surgery 72:3, 859-866
CrossRef367
Kevin G. Billingsley, Charles Maynard, David L. Schwartz, Jason A. Dominitz. (2001) The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population. Cancer 92:5, 1272-1280
CrossRef368
Jaffer A. Ajani, Ritsuko Komaki, Joe B. Putnam, Garrett Walsh, Jon Nesbitt, Peter W. Pisters, Patrick M. Lynch, Ara Vaporciyan, Roy Smythe, Sandeep Lahoti, Issac Raijman, Stephen Swisher, Faye D. Martin, Jack A. Roth. (2001) A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92:2, 279-286
CrossRef369
Jean-Marie Collard, Jean-Bernard Otte, René Fiasse, Pierre-François Laterre, Marc De Kock, Jacques Longueville, David Glineur, Renato Romagnoli, Marc Reynaert, Paul-Jacques Kestens. (2001) Skeletonizing En Bloc Esophagectomy for Cancer. Annals of Surgery 234:1, 25-32
CrossRef370
Simon Law, John Wong. (2001) Esophageal cancer. Current Opinion in Gastroenterology 17:4, 393-399
CrossRef371
Eric L. R. B
CrossRef372
X Jiao. (2001) Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer. European Journal of Cardio-Thoracic Surgery 19:6, 880-886
CrossRef373
Ermanno Ancona, Alberto Ruol, Stefano Santi, Stefano Merigliano, Vanna Chiarion Sileni, Haralabos Koussis, Giovanni Zaninotto, Luigi Bonavina, Alberto Peracchia. (2001) Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer 91:11, 2165-2174
CrossRef374
Takeshi Hori, Yoshito Yamashita, Masaichi Ohira, Yumiko Matsumura, Kazuya Muguruma, Kosei Hirakawa. (2001) A novel orthotopic implantation model of human esophageal carcinoma in nude rats: CD44H mediates cancer cell invasionin vitro andin vivo. International Journal of Cancer 92:4, 489-496
CrossRef375
Jean-Marie Collard. (2001) Exclusive radical surgery for esophageal adenocarcinoma. Cancer 91:6, 1098-1104
CrossRef376
Luigi Bonavina, Davide Soligo, Nadia Quirici, Patrizia Bossolasco, Bruno Cesana, Giorgio Lambertenghi Deliliers, Alberto Peracchia. (2001) Bone marrow—disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 129:1, 15-22
CrossRef377
Frederik Wenz, Harvey Mamon. (2001) Perioperative radiotherapy for cancer of the esophagus. Seminars in Surgical Oncology 20:1, 33-39
CrossRef378
Lawrence E. Harrison. (2000) Is esophageal cancer a surgical disease?. Journal of Surgical Oncology 75:4, 227-231
CrossRef379
Ashesh B. Jani, Philip P. Connell, Valerie J. Vesich, Katherine M. O’Brien, Luci M. Chen. (2000) Analysis of the Role of Adjuvant Chemotherapy for Invasive Carcinoma of the Esophagus. American Journal of Clinical Oncology: Cancer Clinical Trials 23:6, 554-558
CrossRef380
Rebecca Wong, Richard Malthaner. (2000) Esophageal cancer: A systematic review. Current Problems in Cancer 24:6, 293-373
CrossRef381
Stephen G. Swisher, Peter W. T. Pisters, Ritsuko Komaki, Sandeep Lahoti, Jaffer A. Ajani. (2000) Gastroesophageal junction adenocarcinoma. Current Treatment Options in Oncology 1:5, 387-398
CrossRef382
Mustapha Adham, J. Baulieux, F. Mornex, E. de la Roche de Bransat, C. Ducerf, J. C. Souquet, J. P. Gerard. (2000) Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer 89:5, 946-954
CrossRef383
Satdarshan P. S. Monga, Robert Wadleigh, A. Sharma, Houtan Adib, Doris Strader, Gurinder Singh, John W. Harmon, Marlene Berlin, Dulabh K. Monga, Lopa Mishra. (2000) Intratumoral Therapy of Cisplatin/Epinephrine Injectable Gel for Palliation in Patients With Obstructive Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials 23:4, 386-392
CrossRef384
Rebecca KS Wong, Adrian Crellin, Richard Malthaner, Rebecca KS Wong. 2000. Preoperative radiotherapy chemotherapy and surgery versus surgery alone for esophageal cancer. .
CrossRef385
Dennis Blom, Jeffrey H. Peters. (2000) Surgery, radiotherapy, and chemotherapy in carcinoma of the esophagus. Current Opinion in Gastroenterology 16:4, 392-399
CrossRef386
Baba, Natsugoe, Shimada, Nakano, Kusano, Fukumoto, Aikou, Akazawa. (2000) Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. Diseases of the Esophagus 13:2, 136-141
CrossRef387
Andreas Imdahl, Jost Jenkner, Christian Ihling, Klaus-Dieter Rückauer, Eduard Heinrich Farthmann. (2000) Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer?. The American Journal of Surgery 179:6, 514-520
CrossRef388
Richard C. Karl, Robert Schreiber, David Boulware, Scott Baker, Domenico Coppola. (2000) Factors Affecting Morbidity, Mortality, and Survival in Patients Undergoing Ivor Lewis Esophagogastrectomy. Annals of Surgery 231:5, 635-643
CrossRef389
Amitabh Chak, Marcia I. Canto, Gregory S. Cooper, Gerard Isenberg, Joseph Willis, Nathan Levitan, Julie Clayman, Arlene Forastiere, Elisabeth Heath, Michael V. Sivak. (2000) Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 88:8, 1788-1795
CrossRef390
Hubert J. Stein, Andreas Sendler, Ulrich Fink, J.R. Siewert. (2000) MULTIDISCIPLINARY APPROACH TO ESOPHAGEAL AND GASTRIC CANCER. Surgical Clinics of North America 80:2, 659-682
CrossRef391
Philippe Wind, Marie-Helene Roullet, Richard Douard, Ollivier Laccoureye, Daniel Brasnu, Paul-Henri Cugnenc. (2000) Experience in the treatment of synchronous and metachronous carcinoma of the oesophagus and the head and neck. Journal of Surgical Oncology 73:3, 138-142
CrossRef392
T. Conroy, M.C. Kaminsky, D. Peiffert, P. Wolff. (2000) Traitements non chirurgicaux des cancers de l'œsophage. La Revue de Médecine Interne 21:1, 58-73
CrossRef393
Alan G Casson, S.Jane Darnton, Sujata Subramanian, Louise Hiller. (2000) What is the optimal distal resection margin for esophageal carcinoma?. The Annals of Thoracic Surgery 69:1, 205-209
CrossRef394
Ernesto Laterza, Giovanni de’ Manzoni, Pietro Tedesco, Alfredo Guglielmi, Giuseppe Verlato, Claudio Cordiano. (1999) Induction Chemo-Radiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Long-Term Results of a Phase II Study. Annals of Surgical Oncology 6:8, 777-784
CrossRef395
Mark J Krasna, You Sheng Mao, Joshua R Sonett, Gen Tamura, Ray Jones, Mohan Suntharalingam, Stephen J Meltzer. (1999) P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. The Annals of Thoracic Surgery 68:6, 2021-2024
CrossRef396
Philippe Wind, Marie-Hélène Roullet, David Quinaux, Olivier Laccoureye, Daniel Brasnu, Paul-Henri Cugnenc. (1999) Long-term results after esophagectomy for squamous cell carcinoma of the esophagus associated with head and neck cancer. The American Journal of Surgery 178:3, 251-255
CrossRef397
Ziv Gamliel, Mark J. Krasna. (1999) Combined modality therapy for esophageal cancer. Current Oncology Reports 1:2, 149-154
CrossRef398
Shawn Mallery, Malcolm DeCamp, Raphael Bueno, Steven J. Mentzer, David J. Sugarbaker, Scott J. Swanson, Jacques Van Dam. (1999) Pretreatment staging by endoscopic ultrasonography does not predict complete response to neoadjuvant chemoradiation in patients with esophageal carcinoma. Cancer 86:5, 764-769
CrossRef399
(1999) Esophageal Cancer Preoperative Chemotherapy?Can We Justify What We Do?. The American Journal of Gastroenterology 94:9, 2562-2563
CrossRef400
William R. Brugge. (1999) Endoscopic Ultrasound Staging of Esophageal Cancer: Assuming Responsibility. The American Journal of Gastroenterology 94:7, 1724-1727
CrossRef401
Toshimasa Tsujinaka, Hitoshi Shiozaki, Makoto Yamamoto, Masatoshi Inoue, Masahiko Yano, Yuichiro Doki, Morito Monden. (1999) Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma. The American Journal of Surgery 177:6, 503-506
CrossRef402
Masamichi Baba, Shoji Natsugoe, Mario Shimada, Shizuo Nakano, Kazusada Shirao, Chikara Kusano, Toshitaka Fukumoto, Takashi Aikou. (1999) Does preoperative chemotherapy cause adverse effects on the perioperative course of patients undergoing esophagectomy for carcinoma?. The Japanese Journal of Thoracic and Cardiovascular Surgery 47:5, 199-203
CrossRef403
Yoshikazu Tsuchiya, Masahiko Onda, Masao Miyashita, Koji Sasajima. (1999) Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus. Medical Oncology 16:1, 31-37
CrossRef404
Mario Sarbia, Michael Stahl, Ulrich Fink, Hansj
CrossRef405
Charles J. Lightdale. (1999) Esophageal cancer. The American Journal of Gastroenterology 94:1, 20-29
CrossRef406
Kelsen, David P., Ginsberg, Robert, Pajak, Thomas F., Sheahan, Daniel G., Gunderson, Leonard, Mortimer, Joanne, Estes, Norman, Haller, Daniel G., Ajani, Jaffer, Kocha, Walter, Minsky, Bruce D., Roth, Jack A., . (1998) Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer. New England Journal of Medicine 339:27, 1979-1984
Full Text407
Rainer Fietkau, Torsten Libera. (1998) Präoperative Radiochemotherapie des Ösophaguskarzinoms: Segen oder Fluch?. Strahlentherapie und Onkologie 174:11, 598-599
CrossRef408
Douglas O. Faigel, Clifford Deveney, Daniel Phillips, M. Brian Fennerty. (1998) Biopsy-negative malignant esophageal stricture: diagnosis by endoscopic ultrasound. The American Journal of Gastroenterology 93:11, 2257-2260
CrossRef409
C. Alexiou, D. Beggs, F.D. Salama, E.T. Brackenbury, W.E. Morgan. (1998) Surgery for esophageal cancer in elderly patients: The view from Nottingham. The Journal of Thoracic and Cardiovascular Surgery 116:4, 545-553
CrossRef410
John S. Bolton, George M. Fuhrman, William S. Richardson. (1998) ESOPHAGEAL RESECTION FOR CANCER. Surgical Clinics of North America 78:5, 773-794
CrossRef411
Larry L. Shears, Ulysses Ribeiro, John Kane, Adriana Safatle-Ribeiro, Simon Watkins, Mitchell Posner. (1998) Apoptosis In Esophageal Cancer Following Induction Chemoradiotherapy. Journal of Surgical Research 79:1, 20-24
CrossRef412
T. Lerut. (1998) Esophageal surgery at the end of the millennium. The Journal of Thoracic and Cardiovascular Surgery 116:1, 1-20
CrossRef413
Michael Maher, Thomas F. Gorey. (1998) Editorial. Irish Journal of Medical Science 167:3, 130-131
CrossRef414
Paul J Ross, Sheela Rao, David Cunningham. (1998) Chemotherapy of oesophago-gastric cancer. Pathology & Oncology Research 4:2, 87-95
CrossRef415
P. Fuentes, P. Thomas, R. Giudicelli. (1998) Place de la cytoponction échoendoscopiquement guidée dans le bilan d’extension ganglionnaire des cancers de l’œsophage. Acta Endoscopica 28:1, 21-26
CrossRef416
T.S. Maughan, T.D.L. Crosby. (1998) Combined modality treatment in oesophageal carcinoma. Clinical Oncology 10:6, 354-355
CrossRef417
Allgaier, Hans-Peter, Schwacha, Henning, Technau, Katja, Blum, Hubert E., . (1997) Fatal Esophagoaortic Fistula after Placement of a Self-Expanding Metal Stent in a Patient with Esophageal Carcinoma. New England Journal of Medicine 337:24, 1778-1778
Full Text418
J Allen. (1997) Squamous cell carcinoma of the esophagus: a review and update. Surgical Oncology 6:4, 193-200
CrossRef419
A Mahadevan. (1997) The role of radiotherapy in the surgical management of gastrointestinal cancer. Surgical Oncology 6:4, 201-208
CrossRef
- Letters
